IMRIS 20-F 1 Apr 15 2014 FY Annual report (foreign) Financial data

Document_And_Entity_Informatio

Document And Entity Information	12 Months Ended
	Dec. 31, 2014
Document Information [Line Items]
Document Type	20-F
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Entity Registrant Name	IMRIS Inc.
Entity Central Index Key	1489161
Current Fiscal Year End Date	-19
Entity Current Reporting Status	Yes
Trading Symbol	IMRS
Entity Common Stock, Shares Outstanding	62,594,346
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets
Cash	$5,002	$6,382
Restricted cash (note 4)	371	7,500
Accounts receivable (note 5)	8,564	13,979
Unbilled receivables	8,347	12,080
Inventory (note 6)	9,130	10,005
Prepaid expenses and other	3,345	3,067
Assets, Current, Total	34,759	53,013
Property, plant, and equipment, net (note 7)	14,311	14,038
Intangible assets, net (note 8)	7,904	8,999
Goodwill (note 8)	6,498	6,498
Other assets (note 9)	2,012	3,013
Total assets	65,484	85,561
Current liabilities
Accounts payable and accrued liabilities (note 10)	12,995	18,335
Deferred revenue	16,272	9,500
Current portion of long term debt (note 18)	2,456	0
Liabilities, Current, Total	31,723	27,835
Long term debt, net of discount (note 18)	21,026	21,204
Other liabilities	945	1,501
Liabilities, Noncurrent, Total	21,971	22,705
Total liabilities	53,694	50,540
Commitments and contingencies (note 19)
Share capital (note 20)
Common Shares, unlimited number of voting common shares authorized; 62,594,346 and 52,030,966 issued and outstanding at December 31, 2014 and December 31, 2013, respectively	168,854	166,959
Additional paid-in capital	15,367	11,337
Deficit	-174,127	-143,740
Accumulated other comprehensive income	1,696	465
Stockholders' Equity Attributable to Parent, Total	11,790	35,021
Total liabilities and shareholders' equity	$65,484	$85,561

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical)	Dec. 31, 2014	Dec. 31, 2013
Common Shares, issued	62,594,346	52,030,966
Common Shares, outstanding	62,594,346	52,030,966

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenue
Systems	$17,591	$36,459	$47,285
Services	11,300	9,583	5,107
Total Revenue	28,891	46,042	52,392
Cost of sales and services	18,959	30,369	34,594
Gross profit (exclusive of depreciation and amortization shown below)	9,932	15,673	17,798
Operating expenses
Administrative	7,130	12,326	8,224
Sales and marketing	7,129	9,986	9,833
Customer support and operations	9,213	11,357	8,612
Research and development	6,764	17,823	14,556
Depreciation and amortization	2,836	3,486	4,097
Total operating expenses	33,072	54,978	45,322
Operating loss	-23,140	-39,305	-27,524
Other income (expense)
Gain (loss) on asset disposals	-196	-120	19
Foreign exchange	-2,232	-1,208	-125
Interest and other	-4,577	-1,223	-40
Total other income (expense)	-7,005	-2,551	-146
Net loss before taxes	-30,145	-41,856	-27,670
Income tax expense (note 13)	242	144	86
Net loss	-30,387	-42,000	-27,756
Other comprehensive income (loss)
Foreign currency translation adjustment	1,231	818	-195
Other comprehensive income (loss)	1,231	818	-195
Comprehensive loss for the year	($29,156)	($41,182)	($27,951)
Weighted average number of common shares outstanding	52,233,551	50,714,678	45,777,587
Basic and diluted loss per share (note 20)	($0.58)	($0.83)	($0.61)

Consolidated_Statements_of_Sha

Consolidated Statements of Shareholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
In Thousands, except Share data
Beginning Balances at Dec. 31, 2011	$74,559	$144,410	$4,291	($73,984)	($158)
Beginning Balances (in shares) at Dec. 31, 2011		44,975,109
Comprehensive income (loss) for the year	-27,951	0	0	-27,756	-195
Issuance of stock on exercise of employee stock options (in shares)		1,086,102
Issuance of stock on exercise of employee stock options	3,409	3,409	0	0	0
Stock based compensation expense for the year	1,559	0	1,559	0	0
Amount credited to share capital related to shares and warrants issued (in shares)		0
Amount credited to share capital related to shares and warrants issued	-989	0	-989	0	0
Ending Balances at Dec. 31, 2012	50,587	147,819	4,861	-101,740	-353
Ending Balances (in shares) at Dec. 31, 2012		46,061,211
Comprehensive income (loss) for the year	-41,182	0	0	-42,000	818
Issuance of stock on exercise of employee stock options (in shares)		219,755
Issuance of stock on exercise of employee stock options	694	694	0	0	0
Stock based compensation expense for the year	1,885	0	1,885	0	0
Amount credited to share capital related to shares and warrants issued (in shares)		5,750,000
Amount credited to share capital related to shares and warrants issued	18,237	18,446	-209	0	0
Warrant repricing fair value adjustment	4,800	0	4,800	0	0
Ending Balances at Dec. 31, 2013	35,021	166,959	11,337	-143,740	465
Ending Balances (in shares) at Dec. 31, 2013		52,030,966
Comprehensive income (loss) for the year	-29,156	0	0	-30,387	1,231
Stock based compensation expense for the year	1,524	0	1,524	0	0
Amount credited to share capital related to shares and warrants issued (in shares)		10,563,380
Amount credited to share capital related to shares and warrants issued	3,000	1,895	1,105	0	0
Warrant repricing fair value adjustment	1,401	0	1,401	0	0
Ending Balances at Dec. 31, 2014	$11,790	$168,854	$15,367	($174,127)	$1,696
Ending Balances (in shares) at Dec. 31, 2014		62,594,346

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
OPERATING ACTIVITIES
Net loss for the year	($30,387)	($42,000)	($27,756)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,836	3,486	4,097
Stock based compensation	1,524	1,885	1,559
(Gain) loss on asset disposals	196	120	-19
Advance payment	544	314	-1,218
Amortization of debt discount and debt issuance costs	1,884	475	0
Other	-512	2,501	2,144
Changes in operating assets and liabilities:
Accounts receivable	5,415	-2,849	2,838
Unbilled receivables	3,733	-1,113	-3,898
Inventory	875	-3,985	-852
Prepaid expenses and other	-317	3,484	-4,200
Accounts payable and accrued liabilities	-3,473	-2,217	8,632
Deferred revenue	6,772	-682	3,035
Net cash used in operating activities	-10,910	-40,581	-15,638
FINANCING ACTIVITIES
Proceeds from issuance of share capital	3,000	18,931	2,420
Proceeds from long-term debt	500	25,000	0
Payment of debt issuance costs	0	-1,872	0
Net cash provided by financing activities	3,500	42,059	2,420
INVESTING ACTIVITIES
Restricted cash	7,129	-5,580	-1,920
Proceeds from sale of assets	7	0	541
Acquisition of property, plant and equipment	-2,510	-9,179	-4,576
Acquisition of intangible assets	-140	-227	-447
Acquisition of other assets	0	0	-1,877
Net cash provided by (used in) investing activities	4,486	-14,986	-8,279
Foreign currency translation adjustment on cash	1,544	830	132
Decrease in cash	-1,380	-12,678	-21,365
Cash, beginning of year	6,382	19,060	40,425
Cash, end of year	5,002	6,382	19,060
Cash paid during the year for:
Interest	772	16	3
Income taxes	4	359	179
Noncash items during the year:
Payment-in-kind ("PIK") interest	1,791	665	0
Warrant repricing fair value adjustment	$1,401	$0	$0

DESCRIPTION_OF_BUSINESS

DESCRIPTION OF BUSINESS	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
DESCRIPTION OF BUSINESS	1	DESCRIPTION OF BUSINESS
	IMRIS Inc. (“IMRIS”, “the Company”, “we”, “us” or “our”) designs, manufactures and markets the VISIUS Surgical TheatreTM, a multifunctional surgical environment that provides intraoperative vision to clinicians to assist in decision-making and enhance precision in treatment. Designed to meet each hospital’s specific clinical application needs, the VISIUS Surgical Theatre can incorporate MR imaging, CT imaging and x-ray angiography in a number of configurations to provide intraoperative images of diagnostic quality - without introducing additional patient transport risk and delivering real-time information to clinicians while preserving optimal surgical access and techniques. IMRIS sells the VISIUS Surgical Theatres globally to hospitals that deliver clinical services to patients in the neurosurgical, spinal, cerebrovascular and cardiovascular markets. Management believes the primary market for the current product portfolio is comprised of those hospitals having relatively large neurosurgical, cerebrovascular or cardiovascular practices. The Company was incorporated on May 18, 2005 under the Canada Business Corporations Act. The Company’s shares are traded on the Toronto Stock Exchange under the symbol “IM” and on the NASDAQ Global Select Market (“NASDAQ”) under the symbol “IMRS”.
	Liquidity
	The Company recorded a net loss of $30.4 million in 2014 and had cash of $5.0 million as of December 31, 2014. Cash and restricted cash as of December 31, 2014 decreased $8.5 million from December 31, 2013 due to cash used in operations of $10.9 million for the year ended December 31, 2014 primarily related to an overall net loss for the period partially offset by changes in working capital. The Company has not yet achieved profitability and anticipates that it may continue to incur net losses in the foreseeable future. Since inception, the Company has funded its losses through the issuance of equity securities and secondarily through the issuance of debt.
	Our ability to fund our operations beyond the next 12 months is dependent on our ability to meet our planned business operations, effectively manage our working capital needs and generate positive cash flows from deposits on new order bookings.  Many aspects of the Company’s business plans involve management’s judgment and estimates that include factors that could be beyond the Company’s control and actual results could differ. Our cash balances can fluctuate based on the timing of the receipt of cash deposits and payments from customers. These and other factors could cause the Company’s business plans to be unsuccessful which could have a material effect on the Company’s operating results, financial condition and liquidity.
	The Company’s current and anticipated cash resources may be insufficient to support currently forecasted operations. Therefore, in order to execute its business plans, the Company may need to obtain additional debt or equity financing. We believe that if our cash balances are not sufficient to meet our liquidity needs, we will be able to raise additional capital. While there is no guarantee that we can raise additional capital, we have a history of being able to successfully fund the business through the capital markets in the form of equity or debt financing.  If we are not able to raise additional capital, we may need to eliminate or suspend research, development and corporate projects and/or consider other alternatives.
	The Company is currently exploring a number of financing alternatives including (i) raising additional equity financing (the “Equity Financing”), (ii) completing a rights offering to its common shareholders (the “Rights Offering”), (iii) effectively managing working capital, (iv) improving cash flows from operations and (v) other strategic alternatives.
	On March 31, 2015, the Company negotiated an amended Facility Agreement with Deerfield. The Amended Facility Agreement includes a Revolving Loan of up to (a) $0.6 million which shall be available immediately and, (b) if requested by the Company, an amount equal to 50 percent of any additional cash received from the Equity Financing and Rights Offering, provided that the sum of (a) and (b) shall not exceed $3.0 million. The Revolving Loan bears an interest rate of 15 percent and matures March 31, 2016. Additionally, interest payments due in April 2015 and July 2015 pursuant to the Company’s Facility Agreement described in Note 18 herein are due instead in cash on October 15, 2015. Our Facility Agreement contains covenants including a covenant that the Company must maintain cash and cash equivalents, including restricted cash, of at least $7.5 million measured at each quarter end (the “minimum cash balance requirement covenant”). This minimum cash balance requirement covenant was previously waived for March 31, 2015 and June 30, 2015 has also been waived for September 30, 2015 and December 31, 2015.
	In the event that the Equity Financing does not raise a sufficient amount capital, the Company will elect to undertake the Rights Offering. To this end, the Company has entered into an agreement dated March 31, 2015 with Centara Corporation, a company controlled by H. David Graves, Chairman of the Board of the Company, pursuant to which Centara Corporation has agreed (i) to take its pro rata portion of any rights offering of the Company and (ii) to subscribe for and exercise any unexercised rights of other shareholders under the rights offering up to a total amount, together with its pro rata portion, of approximately $3 million. Any rights offering would be subject to applicable regulatory and stock exchange approval.
	Giving consideration to the above, the Company believes cash resources will be sufficient to support operations into the foreseeable future.
	On October 10, 2014 we filed a $30 million shelf registration statement on Form F-3 with the SEC. On October 29, 2014 the shelf registration statement was declared effective by the SEC.  The specifics of any potential future offering, along with the prices and terms of any such securities offered by the Company will be determined at the time of any such offering and will be described in detail in a prospectus supplement filed in connection with such offering.  The shelf registration statement replaced our previously existing shelf registration statement filed on Form F-10, which expired in November 2014.
	Our common stock has been and is likely to continue to be volatile, and an investment in our common stock could decline in value. On August 25, 2014, we received a letter from the NASDAQ stating that for the previous 30 consecutive business days the bid price of the Company's common stock closed below the minimum $1.00 per share required for continued listing under NASDAQ Listing Rule 5450(a)(1). In accordance with NASDAQ Listing Rule 5810(c)(3)(A), the Company had a period of 180 calendar days, or until February 23, 2015, to regain compliance with the minimum bid requirement. On February 13, 2015, the Company received a letter from NASDAQ stating that since the closing bid price of the Company’s common stock had been greater than $1.00 for the last 10 consecutive business days, from January 30 to February 12, they determined that IMRIS was in compliance with Listing Rule 5450(a)(1) and that this matter was then closed.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES		2	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	The accompanying consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”). The significant accounting policies of the Company include the following:
		a)	Basis of consolidation
	The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries: IMRIS, Inc. (United States), IMRIS (Europe) SPRL (Belgium), IMRIS India Private Limited (India), IMRIS KK (Japan), NeuroArm Surgical Limited (Canada), IMRIS Germany GmbH (Germany), IMRIS Medical Technology Service Beijing Co., Ltd. (China) and IMRIS Singapore Pte Ltd. All intercompany transactions and balances are eliminated on consolidation.
		b)	Basis of presentation
	The consolidated financial statements are prepared by the Company in United States Dollars (USD), unless where otherwise stated, and in accordance with U.S. GAAP.
		c)	Use of estimates
	The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting year. Areas where management used subjective judgment include, but are not limited to, the completion percentage applied to program installations, the recognition and measurement of current and deferred income tax assets and liabilities, estimated useful lives of intangible and capital assets, investment tax credits receivable, stock-based compensation costs, collectability and the timing of the collections of accounts receivable, assessment of inventory obsolescence and the valuation and recognition of goodwill and impairment assessments. Actual results could differ significantly from those estimates. Changes in estimates are recorded in the accounting period in which these changes are determined.
		d)	Revenue recognition
	The Company generates revenues from three principal activities: program sales, sales of ancillary products and services and extended maintenance services.
	Revenues for program sales are recognized on a percentage of completion basis as VISIUS Surgical theatres are installed. Sales are recorded using the cost-to-cost method to measure the progress towards completion. Under the cost-to-cost method of accounting, the Company recognizes sales and estimated profit as costs are incurred based on the proportion that the incurred costs bear to total estimated costs. The cost estimation process is based on the professional knowledge and experience of the Company’s engineers and project managers. Actual costs include only those costs that are directly attributable to contract performance with respect to the revenue recognized. Pre-contract costs are expensed unless their costs can be directly associated with a specific anticipated contract and recoverability from that contract is reasonably assured. When adjustments in estimated contract revenues or estimated costs at completion are required, changes from prior estimates are recognized in the current period for the inception to date effect of such changes.
	When estimates of total costs to be incurred on a contract exceed total estimates of revenue to be earned, a provision for the entire loss on contract is recorded in the period in which the loss is determined.
	Funds received from customers in advance of meeting the criteria for revenue recognition are recorded as deferred revenue until such time as the revenue is recognized. Revenues recognized in advance of the criteria for invoicing to the customer are recorded as unbilled receivables where the collection of the receivable is reasonably assured.
	Revenues from ancillary products and services are recognized where there is persuasive evidence of an arrangement and upon delivery or as the services are rendered, respectively. Revenues from extended maintenance service agreements are recognized ratably over the life of the service agreement. Revenues from both ancillary products and services and extended maintenance service agreements are based on pre-determined or determinable sales prices and are only recognized when the collection of the receivable is reasonably assured. Excise taxes are presented on a gross basis and are expensed as incurred.
		d)	Cash and cash equivalents
	Cash equivalents are short-term highly liquid investments that are readily convertible to known amounts of cash with original maturities of three months or less and consist of bank deposits and guaranteed investment certificates. Cash and cash equivalents are carried at fair market value. For cash equivalents, fair value approximates cost because these instruments are subject to an insignificant risk of a change in value. The Company did not hold any cash equivalents at December 31, 2014 or December 31, 2013.
		e)	Accounts receivable and allowance for doubtful accounts
	The accounts receivable balance reflects all amounts invoiced and is presented net of any allowance for doubtful accounts. The Company evaluates the collectability of its accounts receivable on a periodic basis by monitoring the financial condition of its customers, reviewing historical trends and assessing economic circumstances. When collectability becomes uncertain, the Company estimates an allowance for doubtful accounts. Due to the high level of creditworthiness of its client base, the Company has not recognized any allowance for doubtful  accounts.
		f)	Inventory
	Inventories are stated at the lower of cost or market. Cost is determined on a standard cost basis which is defined as the cost of materials plus an allocation of production labor and overhead. Cost of materials is based on the invoiced value of goods. Market is defined as replacement cost as per the definition in Accounting Standards Codification (“ASC”) 330-10. The Company determines an inventory allowance based on an estimate of obsolete inventories.
		g)	Property, plant and equipment
	The Company records all property, plant and equipment acquisitions at their original cost. Once the asset is available for use, recorded amounts are amortized and depreciated over their estimated useful life using the straight-line method at the following rates:
	Computer equipment	3 years
	Office furnishings and equipment	5 years
	Assembly & test equipment	2-5 years
	Demonstration suite & tradeshow equipment	3-5 years
	Leasehold improvements	Lesser of their useful life or the term of lease
		h)	Goodwill and intangible assets
	Goodwill
	Goodwill represents the excess of the purchase price over fair value of the identifiable net tangible assets and intangible assets purchased at the date of acquisition. Goodwill is not amortized, but rather it is tested for impairment annually or more frequently if an event occurs or circumstances change that indicates that goodwill might be impaired. The Company annually tests for goodwill impairment at November 30. Impairment testing for goodwill is done at the reporting unit level, with all goodwill assigned to a reporting unit. IMRIS has one reporting unit.
	The impairment test for goodwill is a two-step process. Step one consists of a comparison of the fair value of its reporting units against their carrying amount, including the goodwill. If the carrying amount of the reporting unit is in excess of its fair value, step two requires the comparison of the implied fair value of the reporting unit’s goodwill against the carrying amount of the reporting unit’s goodwill. Any excess of the carrying value of the reporting unit’s goodwill over the implied fair value of the reporting unit’s goodwill is recorded as an impairment loss.
	The Company used quoted market prices in active markets to determine estimated fair value.
	Patents
	Patents are accounted for at cost. Amortization is based on the estimated useful life, which is generally the life of the patent, using the straight-line method. The average remaining life of the patents at the time of acquisition in May 2005 was 11 years. The patents acquired in the NeuroArm Surgical Limited acquisition in February 2010 are amortized over the estimated useful lives, which range between 13-18 years.
	Computer software
	Computer software is accounted for at cost. Amortization is based on the estimated useful life, which is generally three years, using the straight-line method.
		i)	Impairment of long lived and intangible assets
	Management evaluates the carrying value of its long-lived assets and identifiable intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. To the extent the estimated undiscounted future net cash inflows attributable to the asset are less than the carrying amount, an impairment loss is recognized. The amount of impairment loss to be recorded is the difference between the assets’ carrying value and the net discounted estimated future cash flows.
		j)	Collaborative arrangements
	Revenue resulting from collaborative arrangements is recognized in accordance with the Company’s current revenue recognition policy. The Company accounts for the equipment value that is over and above the cash received from its third party collaborative partner as an advance payment in accordance with ASC 730-20. The current portion of the advance payment is included in prepaid assets, the long-term portion is included in other assets. Once installation is complete the advance payment is amortized over the term of the agreement. Management tests the collaborative arrangements for impairment on a regular basis.
		k)	Research and development
	Research and development costs are expensed as incurred. Costs related to the development of software are capitalized beginning when a product’s technological feasibility has been established and ending when the product is available for general release to the customer. Software development costs are capitalized and amortized over the useful life of the technology.
		l)	Investment tax credits
	The Company is entitled to non-refundable investment tax credits from both the federal and provincial governments in Canada and to refundable investment tax credits from the Province of Manitoba. Investment tax credits are earned as a percentage of eligible current and capital research and development expenditures incurred in each taxation year. Investment tax credits are recognized when realization of the tax credits is more likely than not.
	Non-refundable investment tax credits are included in the determination of the Company’s deferred tax assets. The Company recognizes a corresponding valuation allowance against any deferred asset balance resulting in no impact to the consolidated financial statements. Non-refundable investment tax credits are recognized either as an item on the Consolidated Statement of Comprehensive Loss in the Company’s income tax provision or as a reduction in capital assets depending on where the original costs, which gave rise to the tax credits, are recorded.
	Refundable investment tax credits are included in accounts receivable until they are received. Refundable investment tax credits are recognized either as an item on the Consolidated Statement of Comprehensive Loss in the Company’s research and development expense or as a reduction in capital assets depending on where the original costs, which gave rise to the tax credits, are recorded.
		m)	Stock based compensation
	Stock based compensation awards are measured at fair value at the date of grant and expensed over their vesting or service periods. The fair value of each option is determined using the Black-Scholes option-pricing model. Expected volatilities are based on historical volatility of the Company’s common stock. The risk-free rate for the contractual life of the option is based on the U.S. Treasury yield curve rates in effect at the time of grant. The Company uses historical data to estimate option exercise and employee termination activity within the valuation model. The expected term of stock options granted is based on historical data and represents the period of time that stock options granted are expected to be outstanding. The dividend yield, if applicable, is based on the latest dividend payments made or announced by the date of grant. Forfeitures are estimated based on historical experience and current demographics. See note 11 herein for further information regarding stock based compensation.
		n)	Income taxes
	We record income taxes using the asset and liability approach. Under this method, deferred taxes are recognized based on the expected future tax consequences of differences between the carrying amount of balance sheet items and their corresponding tax basis, using the enacted income tax rates for the years in which the differences are expected to be realized or settled. A valuation allowance is provided to the extent that it is not more likely than not that the deferred tax assets will be realized.
	The Company’s policy is to recognize interest related to income taxes in interest expense and interest income, and recognize penalties in administrative expenses.
		o)	Foreign currency translation
	All monetary assets and liabilities denominated in currencies other than each subsidiary’s functional currency are translated at the applicable period end reporting date exchange rates. Non-monetary assets are translated at the exchange rates prevailing when the asset was acquired. Revenue and expenses are translated at average exchange rates for the period. Exchange gains or losses on translation of foreign currencies transactions are included in the Consolidated Statements of Comprehensive Loss.
	Translation adjustments occurring as a result of the consolidation of subsidiaries whose functional currency is not USD are recorded as a separate component of accumulated other comprehensive income (loss).

RECENTLY_ADOPTED_OR_ISSUED_ACC

RECENTLY ADOPTED OR ISSUED ACCOUNTING PRONOUNCEMENTS	12 Months Ended
	Dec. 31, 2014
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
RECENTLY ADOPTED OR ISSUED ACCOUNTING PRONOUNCEMENTS		3	RECENTLY ADOPTED OR ISSUED ACCOUNTING PRONOUNCEMENTS
	On August 27, 2014, the Financial Accounting Standards Board (“FASB”) issued authoritative guidance (ASU 2014-15), Presentation of Financial Statements—Going Concern. The guidance requires Management to perform interim and annual assessments on whether there are conditions or events that raise substantial doubt about the Company's ability to continue as a going concern within one year of the date the financial statements are issued and to provide related disclosures, if required. The new standard is effective for us for the year ended December 31, 2016 and for subsequent interim periods. The adoption of the standard is not expected to have a material effect on our consolidated financial statements and related disclosures.
	On May 28, 2014, FASB issued authoritative guidance (ASU 2014-09), Revenue from Contracts with Customers, a standard convergence project with the International Accounting Standards Board (“IASB”). The guidance will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for us on January 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. We are evaluating the effect the guidance will have on our consolidated financial statements and related disclosures. We have not yet selected a transition method nor have we determined the effect of the standard on our ongoing financial reporting.

RESTRICTED_CASH

RESTRICTED CASH	12 Months Ended
	Dec. 31, 2014
Restricted Cash and Investments [Abstract]
RESTRICTED CASH		4	RESTRICTED CASH
	As of December 31, 2014, restricted cash consisted of a short-term deposit of $371 that has been pledged as security to our bank for a bank guarantee required for a project in process. As of December 31, 2013, restricted cash consisted of cash and equivalents minimum cash balance of $7,500 related to our long term debt covenant compliance (see note 18. Long Term Debt, net of discount).

ACCOUNTS_RECEIVABLE

ACCOUNTS RECEIVABLE	12 Months Ended
	Dec. 31, 2014
Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]
ACCOUNTS RECEIVABLE		5	ACCOUNTS RECEIVABLE
			December 31, 2014		December 31, 2013
	Accounts receivable, trade		$	8,539	$	13,373
	Commodity taxes receivable			25		246
	Refundable investment tax credit receivable			-		360
			$	8,564	$	13,979
	For the years ended December 31, 2014, 2013 and 2012, due to the high level of creditworthiness of its client base, we have not recognized any allowance for doubtful accounts. For the years ended December 31, 2014, 2013 and 2012, we recorded bad debt expense of $13, $0, and $142.
	For the year ended December 31, 2014, we acquired inventory at cost in exchange for an accounts receivable of $867. This inventory was reallocated to a different customer. No gains or losses were recognized on the transfer.

INVENTORY

INVENTORY	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
INVENTORY	6	INVENTORY
			31-Dec-14		31-Dec-13
	Materials		$	7,545	$	8,655
	Customer support inventory			588		742
	Work in progress			997		608
			$	9,130	$	10,005
	During the years ended December 31, 2014, 2013 and 2012, we wrote down $109, $232 and $290 of inventory and recorded an inventory provision for slow moving and obsolete inventory of $59, $318 and $145.

PROPERTY_PLANT_AND_EQUIPMENT_N

PROPERTY, PLANT AND EQUIPMENT, NET	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT, NET		7	PROPERTY, PLANT AND EQUIPMENT, NET
			December 31, 2014						December 31, 2013
			Cost		Accumulated depreciation		Net book value		Cost		Accumulated depreciation		Net book value
	Computer equipment		$	1,430	$	1,112	$	318	$	2,061	$	1,521	$	540
	Office furnishings & equipment			1,030		804		226		1,019		717		302
	Assembly & test equipment			11,849		8,921		2,928		9,751		7,833		1,918
	Demonstration suite & tradeshow equipment			1,030		816		214		1,757		1,655		102
	Leasehold improvements			1,571		150		1,421		835		658		177
	Asset under construction			9,204		-		9,204		10,999		-		10,999
			$	26,114	$	11,803	$	14,311	$	26,422	$	12,384	$	14,038
	During the years ended December 31, 2014, 2013 and 2012 depreciation of $1,601, $2,257 and $2,864 relating to the property, plant and equipment was charged to operations. As of December 31, 2014, there were no events or changes in circumstances, which would indicate an impairment of property, plant and equipment.
	Assets under construction are primarily related to the development of the Company’s SYMBIS image guided robot.  The assets will be put into service when the final stages of product development are complete.
	In September 2014, we completed construction of the Minnetonka R&D lab which has an estimated life longer than the remaining Minnetonka lease term. We are contractually required to dismantle the lab at the end of our lease. In accordance with FASB ASC 410-20, Asset Retirement Obligations, we recognized the fair value of a liability for an asset retirement obligation in the amount of $100. We capitalized that cost as part of the carrying amount of the research and development lab, which is depreciated on a straight-line basis over 8.5 years.

INTANGIBLE_ASSETS_AND_GOODWILL

INTANGIBLE ASSETS AND GOODWILL	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS AND GOODWILL		8	INTANGIBLE ASSETS AND GOODWILL
	Intangible assets, net
			December 31, 2014						December 31, 2013
			Cost		Accumulated amortization		Net book value		Cost		Accumulated amortization		Net book value
	Patents		$	11,431	$	3,862	$	7,569	$	11,431	$	3,119	$	8,312
	Software			1,298		963		335		1,496		1,053		443
	License			731		731		-		731		487		244
			$	13,460	$	5,556	$	7,904	$	13,658	$	4,659	$	8,999
	During the years ended December 31, 2014, 2013 and 2012 amortization of $1,235, $1,231 and $1,233 relating to the patents and software was charged to operations.
	Based on the intangibles in service as of December 31, 2014, the estimated amortization expense for each of the next five years is as follows:
	2015		$	967
	2016			794
	2017			725
	2018			698
	2019			698
	Thereafter			4,022
	Goodwill
	As of December 31, 2014 and 2013 the Company had goodwill of $6,498 related to the purchase of the assets of a predecessor company. We completed our annual goodwill impairment test in the fourth quarter of 2014 and determined that no impairment existed. In addition, we had no impairments of goodwill in prior years.

OTHER_ASSETS

OTHER ASSETS	12 Months Ended
	Dec. 31, 2014
Other Assets [Abstract]
OTHER ASSETS		9	OTHER ASSETS
			December 31, 2014		December 31, 2013
	Collaborative arrangements (note 15)		$	955	$	1,497
	Debt issuance costs			796		1,253
	Other			261		263
			$	2,012	$	3,013

ACCOUNTS_PAYABLE_AND_ACCRUED_L

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES	12 Months Ended
	Dec. 31, 2014
Accounts Payable and Accrued Liabilities [Abstract]
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES		10	ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
			December 31, 2014		December 31, 2013
	Trade accounts payable		$	6,810	$	8,344
	Accruals			4,027		7,669
	Payroll related accruals			1,376		2,221
	Income tax payable			377		10
	Commodity tax payable			214		19
	Warranty			191		72
			$	12,995	$	18,335
	We record a liability for future warranty costs to repair or replace our products. The warranty term is generally 12 months. The amount of the liability is determined based on management’s historical experience and the best estimate of probable claims under Company warranties. We regularly evaluate the appropriateness of the remaining accrual.
	The following table details the changes in the warranty accrual:
	Balance as of December 31, 2011		$	591
	Accruals			412
	Utilization			-665
	Balance as of December 31, 2012		$	338
	Accruals			192
	Utilization			-458
	Balance as of December 31, 2013		$	72
	Accruals			478
	Utilization			-359
	Balance as of December 31, 2014		$	191

STOCK_BASED_COMPENSATION

STOCK BASED COMPENSATION	12 Months Ended
	Dec. 31, 2014
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
STOCK BASED COMPENSATION		11	STOCK BASED COMPENSATION
	On May 20, 2005, the Board of Directors approved a stock option plan (the “Plan”) for the employees, directors, officers and consultants of the Company and any of its subsidiaries, which govern all options granted under the Plan. At the 2013 Annual Meeting on May 2, 2013, the shareholders reaffirmed the plan. Under the Plan, options to purchase common shares of the Company may be granted by the Board of Directors. The exercise price of the options granted is established by the Board of Directors based on the fair market value of the common shares, as of the date of the grant. The maximum number of common shares, which may be issued pursuant to options granted under the Plan, is equal to 15% of the common shares of the Company outstanding at any time.
	Options granted under the Plan generally vest over a four-year period and may be exercised in whole or in part as to any vested options prior to the expiry time as follows: 25% on or after the first anniversary of the grant date, increasing 6.25% per quarter thereafter until fully vested after four years. Options generally expire six years after the date of the grant. The vesting of options granted under the plan ceases upon the death or the termination of employment of the participant or the participant ceases to be a director. The participant thereafter has 90 days to exercise any vested and unexpired options, after which any unexercised options shall lapse. The Board of Directors, at their discretion, may accelerate the vesting period of individual grants as deemed appropriate.
	The Board of Directors may accelerate the vesting of all unvested options, in the event of certain change of control transactions, including without limitation a takeover bid, merger or other structured acquisition. The Board may further force the exercise of any and all vested options, and/or may cancel or replace any unvested options in any manner the Board deems reasonable, in its unfettered discretion. The Company can satisfy its obligation from the exercise of options by either issuing shares or repurchasing shares on the market. To date the Company has chosen to issue shares and does not expect to repurchase shares from the market to satisfy expected exercises of stock options.
	The outstanding options and the activity relating to these options are as follows:
			Number of			Weighted average			Average			Aggregate
			options			exercise price			remaining			intrinsic
						(CDN$)			contractual			value
									life in years			(CDN$)
	Balance as of December 31, 2011			4,162,061		$	4.23
	Granted			1,390,225			3.6
	Exercised			-1,086,102			2.24
	Forfeited			-151,019			4.38
	Expired			-3,000			1.71
	Balance as of December 31, 2012			4,312,165		$	4.52
	Granted			2,148,146			2.53
	Exercised			-219,755			2.26
	Forfeited			-721,327			4.19
	Expired			-662,247			5.52
	Balance as of December 31, 2013			4,856,982		$	3.66
	Granted			349,015			1.54
	Exercised			-			-
	Forfeited			-1,209,054			3.82
	Expired			-218,746			4.51
	Balance as of December 31, 2014			3,778,197		$	3.36
	Exercisable as of December 31, 2014			1,901,011		$	4.04			3.3		$	-
	Vested and expected to vest as of December 31, 2014			3,402,599		$	3.46			3.8		$	27
	The aggregate intrinsic value, in the table above, represents the total pre-tax intrinsic value (the aggregate difference between the closing stock price of the Company’s common shares on December 31, 2014 and the exercise price for the in-the-money options) that would have been received by the option holders if all in-the-money options had been exercised on December 31, 2014. The total intrinsic value of the stock options exercised during years ended December 31, 2014, 2013 and 2012 calculated using the average market price during the respective year was $0, $133 and $707.
	The following table summarizes options outstanding and exercisable at December 31, 2014:
	Year		Number of			Exercise price			Weighted				Number of	Weighted
	granted		options			range			average				options	average
			outstanding			(CDN$)			exercise price				exercisable	exercise price
									(CDN$)					(CDN$)
	2009			89,251			2.01 to 5.60			4.49			89,251		4.49
	2010			210,435			5.52 to 6.45			5.97			210,435		5.97
	2011			371,085			2.73 to 7.65			4.08			293,561		4.29
	2012			1,146,610			2.73 to 7.18			4.21			728,613		4.34
	2013			1,622,528			1.27 to 3.33			2.58			579,151		2.75
	2014			338,288			0.47 to 1.94			1.53			-		-
				3,778,197			$0.47 to $7.65		$	3.36			1,901,011	$	4.04
	The following assumptions were used in the calculation of the fair value of options granted during the year using the Black-Scholes option-pricing model:
			2014				2013				2012
	Number of options granted during the year			349,015				2,148,146				1,390,225
	Weighted average grant date fair value of stock options granted during the year (CDN$)		$	0.82			$	1.21			$	1.92
	Risk-free interest rate			1.59	%			1.45	%			1.35	%
	Dividend yield			0	%			0	%			0	%
	Expected life of the options			4.9 years				4.25 years				4.25 years
	Expected volatility of the underlying stock			62.13	%			58.81	%			68.29	%
	Expected volatilities are based on the historic volatility of the Company’s shares as this represents the most appropriate basis to determine the expected volatility in future years.
	The estimated grant date fair value of the options is expensed on a straight-line basis over the option’s vesting period. The table below summarizes the effect of recording share based compensation expense for the year:
			2014			2013			2012
	Administrative		$	723		$	939		$	693
	Sales and marketing			387			499			449
	Customer support and operations			231			223			152
	Research and development			183			224			265
	Net decrease in earnings		$	1,524		$	1,885		$	1,559
	The following table presents information on unvested stock options:
			Number of			Weighted average
			options			grant date fair value
						(CDN$)
	Balance as of January 1, 2012			1,603,300		$	2.59
	Granted during the year			1,390,225			1.92
	Vested during the year			-583,388			2.76
	Forfeited during the year			-95,671			1.98
Balance as of December 31, 2012			2,314,466		$	2.17
Granted during the year			2,148,146			1.21
Vested during the year			-845,438			2.26
Forfeited during the year			-458,821			1.89
Balance as of December 31, 2013			3,158,353		$	1.53
Granted during the year			349,015			0.82
Vested during the year			-1,128,345			1.76
Forfeited during the year			-501,837			1.2
Balance as of December 31, 2014			1,877,186		$	1.35
As of December 31, 2014 there was $1,651 of unrecognized stock-based compensation expense related to unvested stock options. This will be expensed over the vesting period, which on a weighted-average basis, results in a period of approximately 2.1 years. The total fair value of stock options vested during the years ended December 31, 2014, 2013 and 2012 was $1,786, $1,841 and $1,614.

DEFINED_CONTRIBUTION_EMPLOYEE_

DEFINED CONTRIBUTION EMPLOYEE PENSION PLAN	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
DEFINED CONTRIBUTION EMPLOYEE PENSION PLAN		12	DEFINED CONTRIBUTION EMPLOYEE PENSION PLAN
	The Company contributes to a defined contribution Employee Pension Plan for all its employees. Contributions to this Plan are expensed as incurred. The Company makes a matching contribution equal to 50% of the employee’s contribution, to a maximum of 3% of the employee’s annual remuneration (subject to regulatory maximums). These employer contributions vest immediately with the employee contribution. The expense for the defined contribution plan during the years ended December 31, 2014, 2013 and 2012 totaled $328, $294 and $271.

INCOME_TAX_EXPENSE

INCOME TAX EXPENSE	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
INCOME TAX EXPENSE		13	INCOME TAX EXPENSE
		a)	Income tax expense
	The components of the Company’s net loss from operations before income taxes, by taxing jurisdiction, were as follows:
			December 31,			December 31,			December 31,
			2014			2013			2012
	Canada		$	-17,998		$	-40,970		$	-28,501
	United States			-12,994			-1,092			361
	Other			847			206			470
			$	-30,145		$	-41,856		$	-27,670
	Income tax expense differs from the amount that would be computed by applying the statutory income tax rates to loss before income taxes. An annual reconciliation of income taxes calculated at the statutory rate to the actual tax provision is as follows:
			December 31,				December 31,				December 31,
			2014				2013				2012
	Statutory federal and provincial tax rate			27	%			27	%			27	%
	Expected tax recovery at statutory rate		$	-8,140			$	-11,301			$	-7,490
	Foreign income taxed at higher rates			-892				-68				25
	Permanent differences and other			529				339				243
	Uncertain tax position			33				-				-
	Research and development tax credits			2,419				-1,569				-
	Deferred Revenue			1,825				-				-
	Deferred True-up			4,225				-				-
	Gain on Sale of Assets			2,703				-				-
	Valuation allowances			-2,460				12,743				7,308
	Income tax expense		$	242			$	144			$	86
		b)	Deferred taxes
	The Company has not recorded any deferred tax assets because a valuation allowance has been provided against the full amount of the deferred tax assets. The balances of deferred taxes as of December 31, 2014 and December 31, 2013 represent the future benefit of unused tax losses and temporary differences between the tax and accounting bases of assets and liabilities.
	The major items giving rise to deferred tax assets and liabilities are presented below:
			December 31, 2014			December 31, 2013
	Non-capital losses carried forward		$	29,668		$	25,550
	Capital assets			2,012			653
	Intangible assets			-3,719			-2,271
	Research and development expenditures			9,293			12,807
	Research and development tax credits			13,947			16,623
	Stock based compensation			750			506
	Reserves not taken for tax purposes			1,050			1,593
	Total deferred tax assets			53,001			55,461
	Valuation allowance			-53,001			-55,461
	Net deferred tax asset		$	-		$	-
	As of December 31, 2014, the Company has the following non-capital losses available to reduce taxable income in future years: $87,969 Canada, $16,493 U.S. federal and $6,951 U.S. state. These losses expire in 2027 and beyond.
	The Company has deductible Scientific Research and Experimental Development expenditures applicable to future years of approximately $34,419. These expenditures have been included in the calculation of deferred taxes above and have no expiry date.
	The Company has unutilized federal and provincial scientific research and experimental development investment tax credits of approximately $9,096 and $7,306, respectively. These credits expire in 2015 and beyond. These expenditures have been included in the calculation of deferred taxes above.
	The Company has adopted the provisions in ASC 740 related to unrecognized tax benefits. ASC 740 provides specific guidance on the recognition, de-recognition and measurement of income tax positions in financial statements, including the accrual of related interest and penalties recorded in interest expense. First, the tax position is evaluated for recognition. An income tax position is recognized when it is more likely than not that it will be sustained upon examination based on its technical merits. If recognition is warranted the benefit is measured as the largest amount that is greater than 50% likely of being realized upon ultimate settlement. As such, we record accruals for items that we believe may be challenged by these taxing authorities. The threshold for recognizing the benefit of a tax return position in the financial statements is that the positive must be more-likely-than-not to be sustained by the taxing authorities based solely on the technical merits of the position. If the recognition threshold is met, the tax benefit is measured and recognized as the largest amount of tax benefit that, in our judgment, is greater than 50 percent likely to be realized.
	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:
			Amount
	Balance at December 31, 2013		$	-
	Additions for tax positions of prior years			33
	Balance at December 31, 2014		$	33
	The balance of unrecognized tax benefits as of December 31, 2014, if recognized, would affect the effective tax rate.
	We recognize interest accrued related to unrecognized tax benefits and penalties as income tax expense. Related to the unrecognized tax benefits noted above, as of December 31, 2014 and 2013 the Company has accrued $6 and $0 for interest and penalties.
	The Company files tax returns in Australia, Belgium, Canada, Japan, Germany, Singapore and the United States. With limited exception, we are no longer subject to income tax examinations by taxing authorities for taxable years before 2010 for Canada and the United States and before 2008 for other jurisdictions.

FINANCIAL_VALUE_MEASUREMENTS

FINANCIAL VALUE MEASUREMENTS	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
FINANCIAL VALUE MEASUREMENTS		14	FINANCIAL VALUE MEASUREMENTS
	Fair value is defined as the exchange price that would be recovered for an asset or paid to transfer a liability (an exit price in the principal or most advantageous market for an asset or liability in an orderly transaction between market participants at the measurement date). Fair value is determined based on the exchange price that would be received for an asset or paid to transfer a liability utilizing a hierarchy of three different valuation techniques, based on the lowest level input that is significant to the fair value measurement in its entirety.
	Financial instruments measured at fair value should be classified into one of three levels that distinguish fair value measurements by the significance of the inputs used for valuation.
	Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities;
	Level 2 - Observable inputs other than Level 1 quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or inputs other than quoted prices that are observable or corroborated by observable market data; and
	Level 3 - Unobservable inputs that are supported by little or no market activity. Valuation techniques are primarily model-based.
	Our financial assets and liabilities that are measured at fair value on a recurring basis have been segregated into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value measurement date in the table below. For cash, fair value approximates cost.
	Financial assets and liabilities measured at fair value as of December 31, 2014 in the consolidated financial statements on a recurring basis are summarized below:
			Level 1		Level 2		Level 3
	Cash		$	5,002	$	-	$	-
	Restricted cash			371		-		-
			$	5,373	$	-	$	-
	Financial assets and liabilities measured at fair value as of December 31, 2013 in the consolidated financial statements on a recurring basis are summarized below:
			Level 1		Level 2		Level 3
	Cash		$	6,382	$	-	$	-
	Restricted cash			7,500		-		-
			$	13,822	$	-	$	-
	Our non-financial assets such as goodwill, intangible assets and property, plant and equipment are recorded at fair value when acquired or subsequently when an impairment is recognized.
	The carrying value of accounts receivable and accounts payable approximate their fair values due to the short-term duration of these items.

COLLABORATIVE_ARRANGEMENTS

COLLABORATIVE ARRANGEMENTS	12 Months Ended
	Dec. 31, 2014
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
COLLABORATIVE ARRANGEMENTS		15	COLLABORATIVE ARRANGEMENTS
	During 2010, we entered into a collaborative arrangement to encourage research, education and patient care activities of mutual benefit in the areas of developing diagnostic and functional assessment capabilities of magnetic resonance imaging for mainstream interventional cardiology and neuroscience. As part of the agreement, we agreed to provide the necessary equipment, maintenance and support staff to achieve the purpose intended by the agreement. The other party has agreed to provide the appropriate clinical validation over a five-year period.
	For the years ended December 31, 2014, 2013 and 2012, we recorded no revenue related to this arrangement. During the years ended December 31, 2014, 2013 and 2012 we charged $230, $230 and $230 to research and development.
	Any future payments to the participant of this agreement will be recognized in accordance with the Company’s current expenditure policies. The classification of these, or any future payments between participants pursuant to this collaborative arrangement, will be based on the nature of the arrangement. All future costs or revenue generated from third parties will be recognized in the income statement on a gross basis.
	During 2011, we entered into a collaborative arrangement with Princess Margaret Hospital to conduct clinical research on IMRIS’ MRgRT™ platform.  As part of the agreement, we developed and manufactured the MRgRT™ platform using IMRIS’ proprietary MR imaging technology in a VISIUS Surgical Theatre. Princess Margaret Hospital agreed to conduct clinical research, which we can use to clinically validate the system and develop a commercially viable version of the platform. During the year ended December 31, 2013 installation was completed and clinical validation could begin.
	Revenue related to this arrangement, for the years ended December 31, 2013 and 2012 was $834 and $3,001, and cost of sales were $958 and $1,582. Costs attributable to the VISIUS Surgical Theatre were classified as cost of sales, as incurred.  Costs attributable to the development of the MRgRT™ platform were recognized as prepaid expenses and other assets. During the year ended December 31, 2013 installation was completed and clinical validation could begin, and $8,294 was recognized as research and development expense.
	During 2012, we entered into a collaborative arrangement to encourage research, education, and patient care activities of mutual benefit in the areas of interventional cerebrovascular science and imaging, with specific focus in the integration of angiography and MR imaging modalities during interventional stroke procedures. As part of a master research agreement, we agreed to provide the necessary equipment, maintenance and support staff to achieve the purpose intended by the agreement. The other party agreed to provide the Company with clinical validation over a five year period.
	Revenue related to this arrangement for the years ended December 31, 2014, 2013 and 2012 was $0, $72 and $2,092, and cost of sales was $0, $91 and $2,092. During the years ended December 31, 2014, 2013 and 2012, we charged $313, $157 and $0 to research and development.

GUARANTEES

GUARANTEES	12 Months Ended
	Dec. 31, 2014
Guarantees [Abstract]
GUARANTEES		16	GUARANTEES
	We periodically enter into agreements that include limited intellectual property indemnifications that are customary in the industry. These guarantees generally require us to indemnify the other party for certain damages and costs incurred as a result of third party intellectual property claims arising from these transactions. The nature of the intellectual property indemnification obligations prevent us from making a reasonable estimate of the maximum potential amount it could be required to pay to its customers and suppliers. We have not made any indemnification payments under such agreements and no amount has been accrued in the accompanying consolidated financial statements with respect to these indemnification obligations.

RESTRUCTURING_COSTS

RESTRUCTURING COSTS	12 Months Ended
	Dec. 31, 2014
Restructuring Costs [Abstract]
RESTRUCTURING COSTS		17	RESTRUCTURING COSTS
	In 2012, we announced our plan to move our operations to the U.S. in order to be closer to the majority of our customers and to have access to critical suppliers and personnel. We expected to incur total costs of approximately $6.8 million related to this activity. These costs comprised of approximately $1.1 million for one-time employee termination benefits, approximately $2.1 million for contract termination costs and approximately $3.6 million for other associated costs such as moving expenses. Since the inception of the plan, we have incurred a total of $1.1 million of one-time employee termination costs, $2.1 million of contract termination costs and $3.4 million of other associated costs. Adjustments are primarily the reversal of prior period accruals for employee severance, retention and relocation costs, as well as foreign exchange rate fluctuations. The accruals were no longer necessary because the employees voluntarily terminated their employment before the retention and severance date. As of December 31, 2013, the plan was substantially complete. As of December 31, 2014, the remaining accruals primarily relate to the Winnipeg, Manitoba location lease, which extends through June 2016. The following is a roll-forward of the accrued liability related to restructuring costs for the year:
			One-time employee termination		Contract termination costs		Other associated costs
			benefits
	Balance as of December 31, 2011		$	-	$	-	$	-
	Incurred			1,383		-		72
	Paid			-42		-		-
	Adjustments			-		-		-
	Balance as of December 31, 2012		$	1,341	$	-	$	72
	Incurred			-		2,125		3,619
	Paid			-879		-		-2,800
	Adjustments			-305		-		-261
	Balance as of December 31, 2013		$	157	$	2,125	$	630
	Incurred			-		-		123
	Paid			-157		-635		-579
	Adjustments			-		-51		-128
	Balance as of December 31, 2014		$	-	$	1,439	$	46
	The following is a summary of costs by income statement classification for the year ended December 31, 2013:
			One-time employee termination		Contract termination costs		Other associated costs
			benefits
	Administrative		$	-66	$	2,125	$	1,112
	Sales and marketing			-		-		18
	Customer support and operations			-69		-		715
	Research and development			-170		-		1,513
	Total		$	-305	$	2,125	$	3,358
	The following is a summary of costs by income statement classification for the year ended December 31, 2012:
			One-time employee termination		Contract termination costs		Other associated costs
			benefits
	Administrative		$	279	$	-	$	21
	Sales and marketing			41		-		-
	Customer support and operations			643		-		22
	Research and development			420		-		29
	Total		$	1,383	$	-	$	72

LONG_TERM_DEBT_NET_OF_DISCOUNT

LONG TERM DEBT, NET OF DISCOUNT	12 Months Ended
	Dec. 31, 2014
Debt Instruments [Abstract]
LONG TERM DEBT, NET OF DISCOUNT	18	LONG TERM DEBT, NET OF DISCOUNT
	On September 16, 2013, we entered into several agreements pursuant to which Deerfield agreed to provide us $25.0 million in funding, which occurred the same day. Pursuant to the terms of the Facility Agreement, we issued Deerfield promissory notes in the aggregate principal amount of $25.0 million. The long-term debt is repayable over five years, with equal payments of the principal amount due on the third, fourth and fifth anniversaries of the date of the disbursement, except if IMRIS achieves certain revenue targets as measured at each anniversary date, upon which we can elect to defer each of the principal payments to subsequent anniversary dates to maturity on its fifth anniversary date. Deerfield may also elect at its option to defer principal payments due on the aforementioned anniversary periods.
	The notes may be prepaid in full after the third anniversary at the approval of Deerfield and at the option of the Company with 20 days’ written notice to Deerfield under the Facility Agreement. Prepayment must be accompanied by a 4% prepayment fee of the principal then outstanding. Deerfield has the right to have the long-term debt repaid at 104% of the principal amount then outstanding in the event the Company completes a major transaction, which includes, but is not limited to, a merger or sale of the Company. If a major transaction occurs prior to the third anniversary of the agreement, the Company will be required to pay all interest that would have been accrued and payable through the third anniversary date. The long-term debt is secured by the Company’s assets.
	The debt agreement contains covenants which are customary for similar credit agreements, including covenants related to financial reporting and notification, payment of indebtedness, taxes and other obligations; compliance with applicable laws; and limitations regarding additional liens, indebtedness, certain acquisitions, investments and dispositions of assets. The debt agreement contains a covenant which requires written consent from Deerfield before declaring or paying any dividend or other distribution on its common shares. Additionally, the Company must maintain cash and cash equivalents, including restricted cash, of at least $7.5 million measured at each quarter end.
	The long-term debt requires interest at 9.0% per annum, payable quarterly. During 2014, the long-term debt effective interest rate was 9.44%. Interest accrued on each of the first five quarters is not paid but is added to the outstanding principal of the notes, resulting in PIK interest of $2,456 and $665 as of December 31, 2014 and 2013. The Company at its option, subject to certain conditions, may elect to satisfy its interest obligations occurring on or after January 1, 2015 in the form of freely tradable common shares of the Company.
	We paid Deerfield a facility fee of $0.5 million and $1.4 million to other professionals involved in the completion of the Facility Agreement. These costs are capitalized and are being amortized over 5 years using the interest method.
	In connection with the Facility Agreement, we issued Deerfield seven-year warrants (the “Deerfield Warrants”) to purchase 6,100,000 shares of the Company’s common stock at an exercise price of $1.94 per share. The exercise of the Deerfield Warrants can be satisfied through a reduction in the principal amount of our outstanding indebtedness to Deerfield, at our option.
	We recorded the promissory notes with an aggregate principal amount of $25.0 million at its face value less a note discount of $4.8 million representing the fair value of the notes and its associated warrants. The note discount is amortized using the interest method. As of December 31, 2013 the unamortized note discount was $4.5 million.
	On September 23, 2014, the exercise price of the Deerfield Warrants was adjusted to $0.70 per share in connection with the covenant waiver granted for the three month period ended September 30, 2014 (see note 1. Description of Business). The exercise price adjustment was considered a debt agreement modification. Under modification accounting, the fair value of the debt immediately before and subsequent to the modification was compared to determine the $1.1 million adjustment to decrease long-term debt and to increase additional paid-in capital.
	On December 24, 2014, the exercise price of the Deerfield Warrants was again adjusted, this time to $0.35386 per warrant in connection with the covenant waiver for the periods commencing October 1, 2014 through and including June 30, 2015. The exercise price adjustment was again considered a debt agreement modification, and the fair value of the debt immediately before and subsequent to the modification was compared to determine the additional $281 adjustment to decrease long-term debt and to increase additional paid-in capital. As of December 31, 2014 the unamortized note discount was $4.5 million and will continue to be amortized using the interest method over the remaining period of 3.75 years.
	The following assumptions were used in the calculation of the fair value of warrants granted or adjusted during the year using the Black-Scholes option-pricing model:
			December 24,			September 23,			September 16,
			2014			2014			2013
	Grant date fair value of warrants granted during the year		$	0.09		$	0.2996		$	0.86
	Risk-free interest rate			1.27	%		1.27	%		2.36	%
	Dividend yield			0	%		0	%		0	%
	Expected life of the warrants			2.98 years			3.23 years			4.25 years
	Expected volatility of the underlying stock			60.93	%		60.93	%		59.96	%
	Expected volatilities are based on the historic volatility of the Company’s shares as this represents the most appropriate basis to determine the expected volatility in future periods.
	In February 2014, we entered into a loan agreement with the City of Minnetonka, Minnesota (“the City”), where the Minnesota Department of Employment and Economic Development has granted us $500 for the purchase and installation of furniture, machinery and equipment and infrastructure improvements necessary for the installation of the aforementioned items. The term of the loan is five years, and bears an interest rate of zero percent. In the event we can document that we have created 75 full-time equivalent jobs at our Minnesota location by February 22, 2015, the City will forgive up to $350 of the loan, with equal monthly payments of the remaining principal balance due beginning January 2016 through January 2019. The loan agreement contains covenants related to financial reporting and notification and is secured by the assets purchased with the loan funds.
	The long-term debt, net of discount, including the current portion of long-term debt, is recorded at its carrying value as of December 31, 2014. The fair value of the debt was approximately $26.6 million as of December 31, 2014. Management estimated the fair value of the long-term debt using Level 2 and Level 3 inputs based on recent financing transactions and on the discounted estimated future cash payments to be made on such long-term debt. The discount rate estimated reflects Management’s judgment as to what the approximate current lending rates for notes or group of notes with similar maturities and credit quality would be if credit markets were operating efficiently and assigns a range of likelihoods to whether the notes will be outstanding through maturity or paid early. Present value has been utilized to estimate the amounts required to be disclosed.
	Interest and other expense includes interest expense, debt discount amortization, debt issuance cost amortization and bank fees (net). Interest and other expense for the years ended December 31, 2014, 2013 and 2012 includes interest expense of $2,423, $665 and $0, debt discount amortization of $494, $340 and $0 and debt issuance cost amortization of $1,387, $133 and $0. The remainder is other net interest income/expense and banking fees.
	The Company has commitments under the Facility Agreement and under the loan agreement with the City requiring future minimum annual principal and interest payments as of December 31, 2014, as follows:
	2015		$	5,401
	2016			10,554
	2017			9,801
	2018			9,040
	2019			14

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	19	COMMITMENTS AND CONTINGENCIES
	Operating leases
	The following table sets forth the minimum rental payments under operating leases with non-cancellable terms in excess of one year as of December 31, 2014:
	2015		$	1,763
	2016			1,493
	2017			1,236
	2018			1,209
	2019			1,202
	Thereafter			4,007
	The Company incurs rent expense under operating leases, which primarily relate to facilities and equipment. The Company incurred rent expense under operating leases of $1,852, $1,681 and $770 for the years ended December 31, 2014, 2013 and 2012.

SHARE_CAPITAL_AND_BASIC_AND_DI

SHARE CAPITAL AND BASIC AND DILUTED LOSS PER SHARE	12 Months Ended
	Dec. 31, 2014
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
SHARE CAPITAL AND BASIC AND DILUTED LOSS PER SHARE	20	SHARE CAPITAL AND BASIC AND DILUTED LOSS PER SHARE
		a)	Authorized
			The Company’s share capital consists of an unlimited number of common shares and an unlimited number of preferred shares. As of December 31, 2014 and 2013, there were no preferred shares outstanding.
		b)	Issued and outstanding
	Pursuant to a private offering (the “Offering”), during the year ended December 31, 2014, the Company issued 10,563,380 units for an offering price of $0.284 per unit for gross proceeds of approximately $3,000. Each unit consists of one common share of the Company and one and a quarter common share purchase warrants. Each warrant is exercisable into one Common Share beginning April 24, 2015 and ending June 24, 2020 at an exercise price per common share of $0.3692.
	The Company did not issue any common shares to employees related to option exercises during the year ended December 31, 2014.
	Pursuant to option exercises, during the year ended December 31, 2013, the Company issued 219,755 common shares to employees for cash consideration of $484. In addition to the cash consideration, $209 was transferred from additional paid-in capital to share capital.
	Pursuant to a public offering, during the year ended December 31, 2013, the Company issued 5,750,000 common shares at a public offering price of $3.50 per share for gross proceeds of approximately $20,100. The difference between the gross proceeds and the amount disclosed in the consolidated statements of shareholders’ equity is due to fees associated with the issuance.
	Pursuant to option exercises, during the year ended December 31, 2012, the Company issued 1,086,102 common shares to employees for cash consideration of $2,420. In addition to the cash consideration, $989 was transferred from additional paid-in capital to share capital.
	When the Company is in a loss position, there are no adjustments to the weighted number of shares outstanding for the purposes of calculating diluted loss per share because to do so would be anti-dilutive.
	As of December 31, 2014, 2013 and 2012, 4,528,172, 463,915 and 452,344 stock options and warrants could potentially dilute basic EPS in the future. These options and warrants were not included in the computation of diluted EPS because to do so would have been anti-dilutive for the years presented.

SEGMENTED_INFORMATION

SEGMENTED INFORMATION	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
SEGMENTED INFORMATION		21	SEGMENTED INFORMATION
	The Company operates as one business segment. The Company develops, assembles and installs VISIUS Surgical Theatres that are used for a variety of medical applications, as well as providing ancillary products and services and extended maintenance services.
	Revenue attributable to geographic locations, based on the location of the customer, is as follows:
			December 31,		December 31,		December 31,
			2014		2013		2012
	Canada		$	1,895	$	3,934	$	3,803
	United States			23,803		24,782		32,569
	Europe and Middle East			702		10,603		2,085
	Asia Pacific			2,491		6,723		13,935
			$	28,891	$	46,042	$	52,392
	During 2014, revenues from two customers accounted for $11,743 or 41% of total revenue for the year. During 2013, revenues from three customers accounted for $20,453 or 44% of total revenue for the year. During 2012, four customers accounted for 44% or $23,054 of total revenues. The revenues from each of these customers individually accounted for more than 10% of the total revenue for the years ended December 31, 2014, 2013 and 2012.

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS		22	RELATED PARTY TRANSACTIONS
	On December 24, 2014, we completed a private placement offering of 10,563,380 units at an offering price of $0.284 per unit. Each unit consisted of one common share and one and a quarter common share purchase warrants. Each whole warrant is exercisable into one common share during the period starting June 24, 2015 and ending on June 24, 2020 at an exercise price per common share of $0.3692. The Offering was negotiated with third parties at arm’s length by a special independent committee of the Company’s Board of Directors. H. David Graves, Carey Diamond, Blaine Hobson, and William Fraser, each of whom are directors of the Company, participated in the Offering individually or through their respective affiliates.
	Until March 31, 2013, we leased air travel time from a corporation that is controlled by the Chairman of IMRIS Inc. The amount charged to travel expenses during the twelve-month period ended December 31, 2013 and 2012, with respect to transactions with this related party totaled $25 and $396. On December 31, 2013, there was no receivable or payable balance owing to this corporation.

QUARTERLY_DATA_UNAUDITED

QUARTERLY DATA (UNAUDITED)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Data [Abstract]
QUARTERLY DATA (UNAUDITED)		23	QUARTERLY DATA (UNAUDITED)
	(Thousands of dollars)		Q4			Q3			Q2			Q1			Q4			Q3			Q2			Q1
			2014			2014			2014			2014			2013			2013			2013			2013
	Revenue		$	9,558		$	6,924		$	4,258		$	8,151		$	9,985		$	17,765		$	10,226		$	8,066
	Cost of sales and services			5,854			4,537			2,342			6,226			7,222			10,984			7,117			5,046
	Gross profit (exclusive of depreciation and amortization shown below)			3,704			2,387			1,916			1,925			2,763			6,781			3,109			3,020
	As a percentage of sales			38.8	%		34.5	%		45	%		23.6	%		27.7	%		38.2	%		30.4	%		37.4	%
	Operating expenses
	Administration			1,841			1,710			1,839			1,740			4,803			2,280			2,833			2,410
	Sales and marketing			1,623			1,791			2,008			1,707			2,905			2,300			2,522			2,259
	Customer support and operations			2,197			2,400			2,388			2,228			3,048			2,889			2,984			2,436
	Research and development			1,869			1,532			1,761			1,602			11,211			2,339			1,534			2,739
	Depreciation and amortization			665			702			702			767			630			963			943			950
	Total operating expenses			8,195			8,135			8,698			8,044			22,597			10,771			10,816			10,794
	Operating loss before the following:			-4,491			-5,748			-6,782			-6,119			-19,834			-3,990			-7,707			-7,774
	Gain (loss) on asset disposals			-2			-206			12			-			-120			-			-			-
	Foreign exchange gain (loss)			-842			-1,357			677			-710			-557			387			-483			-555
	Interest and other expense			-1,358			-1,092			-1,072			-1,055			-992			-195			-3			-33
	Net loss before taxes		$	-6,693		$	-8,403		$	-7,165		$	-7,884		$	-21,503		$	-3,798		$	-8,193		$	-8,362
	Income tax expense (benefit)			374			-11			-138			17			112			6			10			16
	Net loss		$	-7,067		$	-8,392		$	-7,027		$	-7,901		$	-21,615		$	-3,804		$	-8,203		$	-8,378
	Loss per share
	Basic		$	-0.13		$	-0.16		$	-0.14		$	-0.15		$	-0.42		$	-0.07		$	-0.16		$	-0.18
	Diluted		$	-0.13		$	-0.16		$	-0.14		$	-0.15		$	-0.42		$	-0.07		$	-0.16		$	-0.18

COMPARATIVE_FIGURES

COMPARATIVE FIGURES	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block [Abstract]
COMPARATIVE FIGURES		24	COMPARATIVE FIGURES
	Total revenue for 2013 and 2012 has been reclassified to conform to the current year’s presentation. $36,459 and $47,285 has been reclassified from total revenue to systems revenue and $9,583 and $5,107 has been reclassified from total revenue to services revenue for the years ended December 31, 2013 and 2012, respectively.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Basis of consolidation		a)	Basis of consolidation
	The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries: IMRIS, Inc. (United States), IMRIS (Europe) SPRL (Belgium), IMRIS India Private Limited (India), IMRIS KK (Japan), NeuroArm Surgical Limited (Canada), IMRIS Germany GmbH (Germany), IMRIS Medical Technology Service Beijing Co., Ltd. (China) and IMRIS Singapore Pte Ltd. All intercompany transactions and balances are eliminated on consolidation.
Basis of presentation		b)	Basis of presentation
	The consolidated financial statements are prepared by the Company in United States Dollars (USD), unless where otherwise stated, and in accordance with U.S. GAAP.
Use of estimates		c)	Use of estimates
	The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting year. Areas where management used subjective judgment include, but are not limited to, the completion percentage applied to program installations, the recognition and measurement of current and deferred income tax assets and liabilities, estimated useful lives of intangible and capital assets, investment tax credits receivable, stock-based compensation costs, collectability and the timing of the collections of accounts receivable, assessment of inventory obsolescence and the valuation and recognition of goodwill and impairment assessments. Actual results could differ significantly from those estimates. Changes in estimates are recorded in the accounting period in which these changes are determined.
Revenue recognition		d)	Revenue recognition
	The Company generates revenues from three principal activities: program sales, sales of ancillary products and services and extended maintenance services.
	Revenues for program sales are recognized on a percentage of completion basis as VISIUS Surgical theatres are installed. Sales are recorded using the cost-to-cost method to measure the progress towards completion. Under the cost-to-cost method of accounting, the Company recognizes sales and estimated profit as costs are incurred based on the proportion that the incurred costs bear to total estimated costs. The cost estimation process is based on the professional knowledge and experience of the Company’s engineers and project managers. Actual costs include only those costs that are directly attributable to contract performance with respect to the revenue recognized. Pre-contract costs are expensed unless their costs can be directly associated with a specific anticipated contract and recoverability from that contract is reasonably assured. When adjustments in estimated contract revenues or estimated costs at completion are required, changes from prior estimates are recognized in the current period for the inception to date effect of such changes.
	When estimates of total costs to be incurred on a contract exceed total estimates of revenue to be earned, a provision for the entire loss on contract is recorded in the period in which the loss is determined.
	Funds received from customers in advance of meeting the criteria for revenue recognition are recorded as deferred revenue until such time as the revenue is recognized. Revenues recognized in advance of the criteria for invoicing to the customer are recorded as unbilled receivables where the collection of the receivable is reasonably assured.
	Revenues from ancillary products and services are recognized where there is persuasive evidence of an arrangement and upon delivery or as the services are rendered, respectively. Revenues from extended maintenance service agreements are recognized ratably over the life of the service agreement. Revenues from both ancillary products and services and extended maintenance service agreements are based on pre-determined or determinable sales prices and are only recognized when the collection of the receivable is reasonably assured. Excise taxes are presented on a gross basis and are expensed as incurred.
Cash and cash equivalents		d)	Cash and cash equivalents
	Cash equivalents are short-term highly liquid investments that are readily convertible to known amounts of cash with original maturities of three months or less and consist of bank deposits and guaranteed investment certificates. Cash and cash equivalents are carried at fair market value. For cash equivalents, fair value approximates cost because these instruments are subject to an insignificant risk of a change in value. The Company did not hold any cash equivalents at December 31, 2014 or December 31, 2013.
Accounts receivable and allowance for doubtful accounts		e)	Accounts receivable and allowance for doubtful accounts
	The accounts receivable balance reflects all amounts invoiced and is presented net of any allowance for doubtful accounts. The Company evaluates the collectability of its accounts receivable on a periodic basis by monitoring the financial condition of its customers, reviewing historical trends and assessing economic circumstances. When collectability becomes uncertain, the Company estimates an allowance for doubtful accounts. Due to the high level of creditworthiness of its client base, the Company has not recognized any allowance for doubtful  accounts.
Inventory		f)	Inventory
	Inventories are stated at the lower of cost or market. Cost is determined on a standard cost basis which is defined as the cost of materials plus an allocation of production labor and overhead. Cost of materials is based on the invoiced value of goods. Market is defined as replacement cost as per the definition in Accounting Standards Codification (“ASC”) 330-10. The Company determines an inventory allowance based on an estimate of obsolete inventories.
Property, plant, and equipment		g)	Property, plant and equipment
	The Company records all property, plant and equipment acquisitions at their original cost. Once the asset is available for use, recorded amounts are amortized and depreciated over their estimated useful life using the straight-line method at the following rates:
	Computer equipment	3 years
	Office furnishings and equipment	5 years
	Assembly & test equipment	2-5 years
	Demonstration suite & tradeshow equipment	3-5 years
	Leasehold improvements	Lesser of their useful life or the term of lease
Goodwill and intangible assets		h)	Goodwill and intangible assets
	Goodwill
	Goodwill represents the excess of the purchase price over fair value of the identifiable net tangible assets and intangible assets purchased at the date of acquisition. Goodwill is not amortized, but rather it is tested for impairment annually or more frequently if an event occurs or circumstances change that indicates that goodwill might be impaired. The Company annually tests for goodwill impairment at November 30. Impairment testing for goodwill is done at the reporting unit level, with all goodwill assigned to a reporting unit. IMRIS has one reporting unit.
	The impairment test for goodwill is a two-step process. Step one consists of a comparison of the fair value of its reporting units against their carrying amount, including the goodwill. If the carrying amount of the reporting unit is in excess of its fair value, step two requires the comparison of the implied fair value of the reporting unit’s goodwill against the carrying amount of the reporting unit’s goodwill. Any excess of the carrying value of the reporting unit’s goodwill over the implied fair value of the reporting unit’s goodwill is recorded as an impairment loss.
	The Company used quoted market prices in active markets to determine estimated fair value.
	Patents
	Patents are accounted for at cost. Amortization is based on the estimated useful life, which is generally the life of the patent, using the straight-line method. The average remaining life of the patents at the time of acquisition in May 2005 was 11 years. The patents acquired in the NeuroArm Surgical Limited acquisition in February 2010 are amortized over the estimated useful lives, which range between 13-18 years.
	Computer software
	Computer software is accounted for at cost. Amortization is based on the estimated useful life, which is generally three years, using the straight-line method.
Impairment of long lived and intangible assets		i)	Impairment of long lived and intangible assets
	Management evaluates the carrying value of its long-lived assets and identifiable intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. To the extent the estimated undiscounted future net cash inflows attributable to the asset are less than the carrying amount, an impairment loss is recognized. The amount of impairment loss to be recorded is the difference between the assets’ carrying value and the net discounted estimated future cash flows.
Collaborative arrangements		j)	Collaborative arrangements
	Revenue resulting from collaborative arrangements is recognized in accordance with the Company’s current revenue recognition policy. The Company accounts for the equipment value that is over and above the cash received from its third party collaborative partner as an advance payment in accordance with ASC 730-20. The current portion of the advance payment is included in prepaid assets, the long-term portion is included in other assets. Once installation is complete the advance payment is amortized over the term of the agreement. Management tests the collaborative arrangements for impairment on a regular basis.
Research and development		k)	Research and development
	Research and development costs are expensed as incurred. Costs related to the development of software are capitalized beginning when a product’s technological feasibility has been established and ending when the product is available for general release to the customer. Software development costs are capitalized and amortized over the useful life of the technology.
Investment tax credits		l)	Investment tax credits
	The Company is entitled to non-refundable investment tax credits from both the federal and provincial governments in Canada and to refundable investment tax credits from the Province of Manitoba. Investment tax credits are earned as a percentage of eligible current and capital research and development expenditures incurred in each taxation year. Investment tax credits are recognized when realization of the tax credits is more likely than not.
	Non-refundable investment tax credits are included in the determination of the Company’s deferred tax assets. The Company recognizes a corresponding valuation allowance against any deferred asset balance resulting in no impact to the consolidated financial statements. Non-refundable investment tax credits are recognized either as an item on the Consolidated Statement of Comprehensive Loss in the Company’s income tax provision or as a reduction in capital assets depending on where the original costs, which gave rise to the tax credits, are recorded.
	Refundable investment tax credits are included in accounts receivable until they are received. Refundable investment tax credits are recognized either as an item on the Consolidated Statement of Comprehensive Loss in the Company’s research and development expense or as a reduction in capital assets depending on where the original costs, which gave rise to the tax credits, are recorded.
Stock-based compensation		m)	Stock based compensation
	Stock based compensation awards are measured at fair value at the date of grant and expensed over their vesting or service periods. The fair value of each option is determined using the Black-Scholes option-pricing model. Expected volatilities are based on historical volatility of the Company’s common stock. The risk-free rate for the contractual life of the option is based on the U.S. Treasury yield curve rates in effect at the time of grant. The Company uses historical data to estimate option exercise and employee termination activity within the valuation model. The expected term of stock options granted is based on historical data and represents the period of time that stock options granted are expected to be outstanding. The dividend yield, if applicable, is based on the latest dividend payments made or announced by the date of grant. Forfeitures are estimated based on historical experience and current demographics. See note 11 herein for further information regarding stock based compensation.
Income taxes		n)	Income taxes
	We record income taxes using the asset and liability approach. Under this method, deferred taxes are recognized based on the expected future tax consequences of differences between the carrying amount of balance sheet items and their corresponding tax basis, using the enacted income tax rates for the years in which the differences are expected to be realized or settled. A valuation allowance is provided to the extent that it is not more likely than not that the deferred tax assets will be realized.
	The Company’s policy is to recognize interest related to income taxes in interest expense and interest income, and recognize penalties in administrative expenses.
Foreign currency translation		o)	Foreign currency translation
	All monetary assets and liabilities denominated in currencies other than each subsidiary’s functional currency are translated at the applicable period end reporting date exchange rates. Non-monetary assets are translated at the exchange rates prevailing when the asset was acquired. Revenue and expenses are translated at average exchange rates for the period. Exchange gains or losses on translation of foreign currencies transactions are included in the Consolidated Statements of Comprehensive Loss.
	Translation adjustments occurring as a result of the consolidation of subsidiaries whose functional currency is not USD are recorded as a separate component of accumulated other comprehensive income (loss).

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Property Plant and Equipment Estimated Useful Lives	Once the asset is available for use, recorded amounts are amortized and depreciated over their estimated useful life using the straight-line method at the following rates:
	Computer equipment	3 years
	Office furnishings and equipment	5 years
	Assembly & test equipment	2-5 years
	Demonstration suite & tradeshow equipment	3-5 years
	Leasehold improvements	Lesser of their useful life or the term of lease

ACCOUNTS_RECEIVABLE_Tables

ACCOUNTS RECEIVABLE (Tables)	12 Months Ended
	Dec. 31, 2014
Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net [Abstract]
ACCOUNTS RECEIVABLE		December 31, 2014		December 31, 2013
	Accounts receivable, trade	$	8,539	$	13,373
	Commodity taxes receivable		25		246
	Refundable investment tax credit receivable		-		360
		$	8,564	$	13,979

INVENTORY_Tables

INVENTORY (Tables)	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
INVENTORY		December 31, 2014		December 31, 2013
	Materials	$	7,545	$	8,655
	Customer support inventory		588		742
	Work in progress		997		608
		$	9,130	$	10,005

PROPERTY_PLANT_AND_EQUIPMENT_N1

PROPERTY, PLANT AND EQUIPMENT, NET (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment		December 31, 2014						December 31, 2013
		Cost		Accumulated depreciation		Net book value		Cost		Accumulated depreciation		Net book value
	Computer equipment	$	1,430	$	1,112	$	318	$	2,061	$	1,521	$	540
	Office furnishings & equipment		1,030		804		226		1,019		717		302
	Assembly & test equipment		11,849		8,921		2,928		9,751		7,833		1,918
	Demonstration suite & tradeshow equipment		1,030		816		214		1,757		1,655		102
	Leasehold improvements		1,571		150		1,421		835		658		177
	Asset under construction		9,204		-		9,204		10,999		-		10,999
		$	26,114	$	11,803	$	14,311	$	26,422	$	12,384	$	14,038

INTANGIBLE_ASSETS_AND_GOODWILL1

INTANGIBLE ASSETS AND GOODWILL (Tables)	12 Months Ended
	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Finite-Lived Intangible Assets		December 31, 2014						December 31, 2013
		Cost		Accumulated amortization		Net book value		Cost		Accumulated amortization		Net book value
	Patents	$	11,431	$	3,862	$	7,569	$	11,431	$	3,119	$	8,312
	Software		1,298		963		335		1,496		1,053		443
	License		731		731		-		731		487		244
		$	13,460	$	5,556	$	7,904	$	13,658	$	4,659	$	8,999
Finite-Lived Intangible Assets, Future Amortization Expense	Based on the intangibles in service as of December 31, 2014, the estimated amortization expense for each of the next five years is as follows:
	2015	$	967
	2016		794
	2017		725
	2018		698
	2019		698
	Thereafter		4,022

OTHER_ASSETS_Tables

OTHER ASSETS (Tables)	12 Months Ended
	Dec. 31, 2014
Other Assets [Abstract]
OTHER ASSETS		December 31, 2014		December 31, 2013
	Collaborative arrangements (note 15)	$	955	$	1,497
	Debt issuance costs		796		1,253
	Other		261		263
		$	2,012	$	3,013

ACCOUNTS_PAYABLE_AND_ACCRUED_L1

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2014
Accounts Payable and Accrued Liabilities [Abstract]
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES		December 31, 2014		December 31, 2013
	Trade accounts payable	$	6,810	$	8,344
	Accruals		4,027		7,669
	Payroll related accruals		1,376		2,221
	Income tax payable		377		10
	Commodity tax payable		214		19
	Warranty		191		72
		$	12,995	$	18,335
Changes In The Warranty Accrual	The following table details the changes in the warranty accrual:
	Balance as of December 31, 2011	$	591
	Accruals		412
	Utilization		-665
	Balance as of December 31, 2012	$	338
	Accruals		192
	Utilization		-458
	Balance as of December 31, 2013	$	72
	Accruals		478
	Utilization		-359
	Balance as of December 31, 2014	$	191

STOCK_BASED_COMPENSATION_Table

STOCK BASED COMPENSATION (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
Outstanding options and the activity relating to these options	The outstanding options and the activity relating to these options are as follows:
		Number of options			Weighted average exercise price			Average remaining contractual life			Aggregate intrinsic value (CDN$)
					(CDN$)			in years
	Balance as of December 31, 2011		4,162,061		$	4.23
	Granted		1,390,225			3.6
	Exercised		-1,086,102			2.24
	Forfeited		-151,019			4.38
	Expired		-3,000			1.71
	Balance as of December 31, 2012		4,312,165		$	4.52
	Granted		2,148,146			2.53
	Exercised		-219,755			2.26
	Forfeited		-721,327			4.19
	Expired		-662,247			5.52
	Balance as of December 31, 2013		4,856,982		$	3.66
	Granted		349,015			1.54
	Exercised		-			-
	Forfeited		-1,209,054			3.82
	Expired		-218,746			4.51
	Balance as of December 31, 2014		3,778,197		$	3.36
	Exercisable as of December 31, 2014		1,901,011		$	4.04			3.3		$	-
	Vested and expected to vest as of December 31, 2014		3,402,599		$	3.46			3.8		$	27
Options outstanding and exercisable	The following table summarizes options outstanding and exercisable at December 31, 2014:
	Year granted	Number of options outstanding			Exercise price range			Weighted average exercise price				Number of options exercisable	Weighted average exercise price
					(CDN$)			(CDN$)					(CDN$)
	2009		89,251			2.01 to 5.60			4.49			89,251		4.49
	2010		210,435			5.52 to 6.45			5.97			210,435		5.97
	2011		371,085			2.73 to 7.65			4.08			293,561		4.29
	2012		1,146,610			2.73 to 7.18			4.21			728,613		4.34
	2013		1,622,528			1.27 to 3.33			2.58			579,151		2.75
	2014		338,288			0.47 to 1.94			1.53			-		-
			3,778,197			$0.47 to $7.65		$	3.36			1,901,011	$	4.04
Fair value of option grants issued was estimated at the date of grant using the Black-Scholes option-pricing model	The following assumptions were used in the calculation of the fair value of options granted during the year using the Black-Scholes option-pricing model:
		2014				2013				2012
	Number of options granted during the year		349,015				2,148,146				1,390,225
	Weighted average grant date fair value of stock options granted during the year (CDN$)	$	0.82			$	1.21			$	1.92
	Risk-free interest rate		1.59	%			1.45	%			1.35	%
	Dividend yield		0	%			0	%			0	%
	Expected life of the options		4.9 years				4.25 years				4.25 years
	Expected volatility of the underlying stock		62.13	%			58.81	%			68.29	%
Effect of recording shared based compensation expense	The table below summarizes the effect of recording share based compensation expense for the year:
		2014			2013			2012
	Administrative	$	723		$	939		$	693
	Sales and marketing		387			499			449
	Customer support and operations		231			223			152
	Research and development		183			224			265
	Net decrease in earnings	$	1,524		$	1,885		$	1,559
Summary of unvested stock options	The following table presents information on unvested stock options:
		Number of options				Weighted average grant date fair value
						(CDN$)
	Balance as of January 1, 2012		1,603,300		$	2.59
	Granted during the year		1,390,225			1.92
	Vested during the year		-583,388			2.76
	Forfeited during the year		-95,671			1.98
	Balance as of December 31, 2012		2,314,466		$	2.17
	Granted during the year		2,148,146			1.21
	Vested during the year		-845,438			2.26
	Forfeited during the year		-458,821			1.89
	Balance as of December 31, 2013		3,158,353		$	1.53
	Granted during the year		349,015			0.82
	Vested during the year		-1,128,345			1.76
	Forfeited during the year		-501,837			1.2
	Balance as of December 31, 2014		1,877,186		$	1.35

INCOME_TAX_EXPENSE_Tables

INCOME TAX EXPENSE (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Company's loss from operations before income taxes, by taxing jurisdiction	The components of the Company’s net loss from operations before income taxes, by taxing jurisdiction, were as follows:
		December 31,			December 31,			December 31,
		2014			2013			2012
	Canada	$	-17,998		$	-40,970		$	-28,501
	United States		-12,994			-1,092			361
	Other		847			206			470
		$	-30,145		$	-41,856		$	-27,670
Annual reconciliation of income taxes calculated at the statutory rate to the actual tax provision	An annual reconciliation of income taxes calculated at the statutory rate to the actual tax provision is as follows:
		December 31,				December 31,				December 31,
		2014				2013				2012
	Statutory federal and provincial tax rate		27	%			27	%			27	%
	Expected tax recovery at statutory rate	$	-8,140			$	-11,301			$	-7,490
	Foreign income taxed at higher rates		-892				-68				25
	Permanent differences and other		529				339				243
	Uncertain tax position		33				-				-
	Research and development tax credits		2,419				-1,569				-
	Deferred Revenue		1,825				-				-
	Deferred True-up		4,225				-				-
	Gain on Sale of Assets		2,703				-				-
	Valuation allowances		-2,460				12,743				7,308
	Income tax expense	$	242			$	144			$	86
Major items giving rise to deferred tax assets and liabilities	The major items giving rise to deferred tax assets and liabilities are presented below:
		December 31, 2014			December 31, 2013
	Non-capital losses carried forward	$	29,668		$	25,550
	Capital assets		2,012			653
	Intangible assets		-3,719			-2,271
	Research and development expenditures		9,293			12,807
	Research and development tax credits		13,947			16,623
	Stock based compensation		750			506
	Reserves not taken for tax purposes		1,050			1,593
	Total deferred tax assets		53,001			55,461
	Valuation allowance		-53,001			-55,461
	Net deferred tax asset	$	-		$	-
Schedule of Unrecognized Tax Benefits	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:
		Amount
	Balance at December 31, 2013	$	-
	Additions for tax positions of prior years		33
	Balance at December 31, 2014	$	33

FINANCIAL_VALUE_MEASUREMENTS_T

FINANCIAL VALUE MEASUREMENTS (Tables)	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Financial assets and liabilities measured at fair value in the consolidated financial statements
	Financial assets and liabilities measured at fair value as of December 31, 2014 in the consolidated financial statements on a recurring basis are summarized below:
		Level 1		Level 2		Level 3
	Cash	$	5,002	$	-	$	-
	Restricted cash		371		-		-
		$	5,373	$	-	$	-
	Financial assets and liabilities measured at fair value as of December 31, 2013 in the consolidated financial statements on a recurring basis are summarized below:
		Level 1		Level 2		Level 3
	Cash	$	6,382	$	-	$	-
	Restricted cash		7,500		-		-
		$	13,822	$	-	$	-

RESTRUCTURING_COSTS_Tables

RESTRUCTURING COSTS (Tables)	12 Months Ended
	Dec. 31, 2014
Restructuring Costs [Abstract]
Reconciliation of the costs incurred	The following is a roll-forward of the accrued liability related to restructuring costs for the year:
		One-time employee termination		Contract termination costs		Other associated costs
		benefits
	Balance as of December 31, 2011	$	-	$	-	$	-
	Incurred		1,383		-		72
	Paid		-42		-		-
	Adjustments		-		-		-
	Balance as of December 31, 2012	$	1,341	$	-	$	72
	Incurred		-		2,125		3,619
	Paid		-879		-		-2,800
	Adjustments		-305		-		-261
	Balance as of December 31, 2013	$	157	$	2,125	$	630
	Incurred		-		-		123
	Paid		-157		-635		-579
	Adjustments		-		-51		-128
	Balance as of December 31, 2014	$	-	$	1,439	$	46
Summary of costs by income statement classification	The following is a summary of costs by income statement classification for the year ended December 31, 2013:
		One-time employee termination		Contract termination costs		Other associated costs
		benefits
	Administrative	$	-66	$	2,125	$	1,112
	Sales and marketing		-		-		18
	Customer support and operations		-69		-		715
	Research and development		-170		-		1,513
	Total	$	-305	$	2,125	$	3,358
	The following is a summary of costs by income statement classification for the year ended December 31, 2012:
		One-time employee termination		Contract termination costs		Other associated costs
		benefits
	Administrative	$	279	$	-	$	21
	Sales and marketing		41		-		-
	Customer support and operations		643		-		22
	Research and development		420		-		29
	Total	$	1,383	$	-	$	72

LONG_TERM_DEBT_NET_OF_DISCOUNT1

LONG TERM DEBT, NET OF DISCOUNT (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Instruments [Abstract]
Fair Value Of Warrants Granted During The Year Using The Black-Scholes Option-Pricing Model	The following assumptions were used in the calculation of the fair value of warrants granted or adjusted during the year using the Black-Scholes option-pricing model:
		December 24,			September 23,			September 16,
		2014			2014			2013
	Grant date fair value of warrants granted during the year	$	0.09		$	0.2996		$	0.86
	Risk-free interest rate		1.27	%		1.27	%		2.36	%
	Dividend yield		0	%		0	%		0	%
	Expected life of the warrants		2.98 years			3.23 years			4.25 years
	Expected volatility of the underlying stock		60.93	%		60.93	%		59.96	%
Commitments Under The Facility Agreement Requiring Future Minimum Annual Principal And Interest Payments	The Company has commitments under the Facility Agreement and under the loan agreement with the City requiring future minimum annual principal and interest payments as of December 31, 2014, as follows:
	2015	$	5,401
	2016		10,554
	2017		9,801
	2018		9,040
	2019		14

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments under operating leases requiring future minimum annual lease payments	The following table sets forth the minimum rental payments under operating leases with non-cancellable terms in excess of one year as of December 31, 2014:
	2015	$	1,763
	2016		1,493
	2017		1,236
	2018		1,209
	2019		1,202
	Thereafter		4,007

SEGMENTED_INFORMATION_Tables

SEGMENTED INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Revenue attributable to geographic locations, based on the location of the customer	Revenue attributable to geographic locations, based on the location of the customer, is as follows:
		December 31,		December 31,		December 31,
		2014		2013		2012
	Canada	$	1,895	$	3,934	$	3,803
	United States		23,803		24,782		32,569
	Europe and Middle East		702		10,603		2,085
	Asia Pacific		2,491		6,723		13,935
		$	28,891	$	46,042	$	52,392

QUARTERLY_DATA_UNAUDITED_Table

QUARTERLY DATA (UNAUDITED) (Tables)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Data [Abstract]
Quarterly Financial Information	(Thousands of dollars)	Q4			Q3			Q2			Q1			Q4			Q3			Q2			Q1
		2014			2014			2014			2014			2013			2013			2013			2013
	Revenue	$	9,558		$	6,924		$	4,258		$	8,151		$	9,985		$	17,765		$	10,226		$	8,066
	Cost of sales and services		5,854			4,537			2,342			6,226			7,222			10,984			7,117			5,046
	Gross profit (exclusive of depreciation and amortization shown below)		3,704			2,387			1,916			1,925			2,763			6,781			3,109			3,020
	As a percentage of sales		38.8	%		34.5	%		45	%		23.6	%		27.7	%		38.2	%		30.4	%		37.4	%
	Operating expenses
	Administration		1,841			1,710			1,839			1,740			4,803			2,280			2,833			2,410
	Sales and marketing		1,623			1,791			2,008			1,707			2,905			2,300			2,522			2,259
	Customer support and operations		2,197			2,400			2,388			2,228			3,048			2,889			2,984			2,436
	Research and development		1,869			1,532			1,761			1,602			11,211			2,339			1,534			2,739
	Depreciation and amortization		665			702			702			767			630			963			943			950
	Total operating expenses		8,195			8,135			8,698			8,044			22,597			10,771			10,816			10,794
	Operating loss before the following:		-4,491			-5,748			-6,782			-6,119			-19,834			-3,990			-7,707			-7,774
	Gain (loss) on asset disposals		-2			-206			12			-			-120			-			-			-
	Foreign exchange gain (loss)		-842			-1,357			677			-710			-557			387			-483			-555
	Interest and other expense		-1,358			-1,092			-1,072			-1,055			-992			-195			-3			-33
	Net loss before taxes	$	-6,693		$	-8,403		$	-7,165		$	-7,884		$	-21,503		$	-3,798		$	-8,193		$	-8,362
	Income tax expense (benefit)		374			-11			-138			17			112			6			10			16
	Net loss	$	-7,067		$	-8,392		$	-7,027		$	-7,901		$	-21,615		$	-3,804		$	-8,203		$	-8,378
	Loss per share
	Basic	$	-0.13		$	-0.16		$	-0.14		$	-0.15		$	-0.42		$	-0.07		$	-0.16		$	-0.18
	Diluted	$	-0.13		$	-0.16		$	-0.14		$	-0.15		$	-0.42		$	-0.07		$	-0.16		$	-0.18

DESCRIPTION_OF_BUSINESS_Detail

DESCRIPTION OF BUSINESS (Details Textual) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Oct. 10, 2014	Aug. 25, 2014	Sep. 16, 2013	Dec. 31, 2011
Entity Incorporation, Date Of Incorporation									18-May-05
Cash And Restricted Cash Decreased									$8,500,000	$8,500,000
Net Cash Provided by (Used in) Operating Activities, Total									10,900,000
Cash and Cash Equivalents, At Carrying Value	5,002,000				6,382,000				5,002,000	6,382,000	19,060,000				40,425,000
Shelf Offering Value												30,000,000
Share Price													$1
Minimum Amount Maintain Cash And Cash Equivalents Including Restricted Cash	7,500,000								7,500,000					7,500,000
Net Income (Loss) Attributable To Parent	-7,067,000	-8,392,000	-7,027,000	-7,901,000	-21,615,000	-3,804,000	-8,203,000	-8,378,000	-30,387,000	-42,000,000	-27,756,000
Line of Credit Facility, Description									The Amended Facility Agreement includes a Revolving Loan of up to (a) $0.6 million which shall be available immediately and, (b) if requested by the Company, an amount equal to 50 percent of any additional cash received from the Equity Financing and Rights Offering, provided that the sum of (a) and (b) shall not exceed $3.0 million.
Rights Offering Value	$3,000,000								$3,000,000

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Leasehold improvements	Lesser of their useful life or the term of lease
Property, Plant and Equipment, Useful Life	8 years 6 months
Computer equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Office furnishings & equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Assembly & Test Equipment | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Assembly & Test Equipment | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	2 years
Demonstration suite & tradeshow equipment | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Demonstration suite & tradeshow equipment | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years

SUMMARY_OF_SIGNIFICANT_ACCOUNT4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Textual)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2010	Dec. 31, 2005
Accounting Policies [Line Items]
Property, Plant and Equipment, Depreciation Methods	straight-line method
Finite-Lived Intangible Assets, Amortization Method	straight-line method
Nasl [Member] | Minimum [Member]
Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life		13 years
Nasl [Member] | Maximum [Member]
Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life		18 years
Patents
Accounting Policies [Line Items]
Finite-Lived Intangible Asset, Useful Life			11 years

RESTRICTED_CASH_Details_Textua

RESTRICTED CASH (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted Cash And Cash Equivalents At Carrying Value	$371	$7,500

ACCOUNTS_RECEIVABLE_Details

ACCOUNTS RECEIVABLE (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts Receivable Net Current	$8,564	$13,979
Accounts receivable, trade
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts Receivable Net Current	8,539	13,373
Commodity taxes receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts Receivable Net Current	25	246
Refundable investment tax credit receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts Receivable Net Current	$0	$360

ACCOUNTS_RECEIVABLE_Details_Te

ACCOUNTS RECEIVABLE (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Provision for Doubtful Accounts	$13,000	$0	$142,000
Accounts Receivable	$867

INVENTORY_Details

INVENTORY (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Materials	$7,545	$8,655
Customer support inventory	588	742
Work in progress	997	608
Inventory Net	$9,130	$10,005

INVENTORY_Details_Textual

INVENTORY (Details Textual) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Inventory Write-down	$109	$232	$290
Provision For Slow Moving and Obsolete Inventory	$59	$318	$145

PROPERTY_PLANT_AND_EQUIPMENT_N2

PROPERTY, PLANT AND EQUIPMENT, NET (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]
Cost	$26,114	$26,422
Accumulated depreciation	11,803	12,384
Net book value	14,311	14,038
Computer equipment
Property, Plant and Equipment [Line Items]
Cost	1,430	2,061
Accumulated depreciation	1,112	1,521
Net book value	318	540
Office furnishings & equipment
Property, Plant and Equipment [Line Items]
Cost	1,030	1,019
Accumulated depreciation	804	717
Net book value	226	302
Assembly & test equipment
Property, Plant and Equipment [Line Items]
Cost	11,849	9,751
Accumulated depreciation	8,921	7,833
Net book value	2,928	1,918
Demonstration suite & tradeshow equipment
Property, Plant and Equipment [Line Items]
Cost	1,030	1,757
Accumulated depreciation	816	1,655
Net book value	214	102
Leasehold improvements
Property, Plant and Equipment [Line Items]
Cost	1,571	835
Accumulated depreciation	150	658
Net book value	1,421	177
Asset under construction
Property, Plant and Equipment [Line Items]
Cost	9,204	10,999
Accumulated depreciation	0	0
Net book value	$9,204	$10,999

PROPERTY_PLANT_AND_EQUIPMENT_N3

PROPERTY, PLANT AND EQUIPMENT, NET (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]
Depreciation	$1,601,000	$2,257,000	$2,864,000
Property, Plant and Equipment Impairment or Disposal Disclosure	As of December 31, 2014, there were no events or changes in circumstances, which would indicate an impairment of property, plant and equipment.
Asset Retirement Obligation	$100
Property, Plant and Equipment, Useful Life	8 years 6 months

INTANGIBLE_ASSETS_AND_GOODWILL2

INTANGIBLE ASSETS AND GOODWILL (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]
Cost	$13,460	$13,658
Accumulated amortization	5,556	4,659
Net book value	7,904	8,999
Patents
Finite-Lived Intangible Assets [Line Items]
Cost	11,431	11,431
Accumulated amortization	3,862	3,119
Net book value	7,569	8,312
Software
Finite-Lived Intangible Assets [Line Items]
Cost	1,298	1,496
Accumulated amortization	963	1,053
Net book value	335	443
License
Finite-Lived Intangible Assets [Line Items]
Cost	731	731
Accumulated amortization	731	487
Net book value	$0	$244

INTANGIBLE_ASSETS_AND_GOODWILL3

INTANGIBLE ASSETS AND GOODWILL (Details 1) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
2015	$967
2016	794
2017	725
2018	698
2019	698
Thereafter	$4,022

INTANGIBLE_ASSETS_AND_GOODWILL4

INTANGIBLE ASSETS AND GOODWILL (Details Textual) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Amortization of Intangible Assets	$1,235	$1,231	$1,233
Good Faith and Margin Deposits with Broker-Dealers	$6,498	$6,498

OTHER_ASSETS_Details

OTHER ASSETS (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Collaborative arrangements (note 15)	$955	$1,497
Debt issuance costs	796	1,253
Other	261	263
Other assets	$2,012	$3,013

ACCOUNTS_PAYABLE_AND_ACCRUED_L2

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Trade accounts payable	$6,810	$8,344
Accruals	4,027	7,669
Payroll related accruals	1,376	2,221
Income tax payable	377	10
Commodity tax payable	214	19
Warranty	191	72	338	591
Accounts payable and accrued liabilities	$12,995	$18,335

ACCOUNTS_PAYABLE_AND_ACCRUED_L3

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details 1) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Balance at beginning of the year	$72	$338	$591
Accruals	478	192	412
Utilization	-359	-458	-665
Balance at end of the year	$191	$72	$338

STOCK_BASED_COMPENSATION_Detai

STOCK BASED COMPENSATION (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Number of options
Number of options, Beginning Balance	4,856,982	4,312,165	4,162,061
Number of options, Granted	349,015	2,148,146	1,390,225
Number of options, Exercised	0	-219,755	-1,086,102
Number of options, Forfeited	-1,209,054	-721,327	-151,019
Number of options, Expired	-218,746	-662,247	-3,000
Number of options, Ending Balance	3,778,197	4,856,982	4,312,165
Number of options, Exercisable	1,901,011
Number of options, Vested and expected to vest	3,402,599
Weighted average exercise price (CDN$)
Weighted average exercise price, Begining balance	$3.66	$4.52	$4.23
Weighted average exercise price, Granted	$1.54	$2.53	$3.60
Weighted average exercise price, Exercised	$0	$2.26	$2.24
Weighted average exercise price, Forfeited	$3.82	$4.19	$4.38
Weighted average exercise price, Expired	$4.51	$5.52	$1.71
Weighted average exercise price, Ending balance	$3.36	$3.66	$4.52
Weighted average exercise price, Exercisable as of December 31, 2014	$4.04
Weighted average exercise price, Vested and expected to vest as of December 31, 2014	$3.46
Average remaining contractual life in years
Average remaining contractual life in years, Exercisable as of December 31, 2014	3 years 3 months 18 days
Average remaining contractual life in years, Vested and expected to vest as of December 31, 2014	3 years 9 months 18 days
Aggregate intrinsic value (CDN$)
Aggregate intrinsic value, Exercisable as of December 31, 2014	$0
Aggregate intrinsic value, Vested and expected to vest as of December 31, 2014	$27

STOCK_BASED_COMPENSATION_Detai1

STOCK BASED COMPENSATION (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	3,778,197	4,856,982	4,312,165	4,162,061
Exercise price range minimum	$0.47
Exercise price range maximum	$7.65
Weighted average exercise price (CDN$)	$3.36	$3.66	$4.52	$4.23
Number of options exercisable	1,901,011
Weighted average exercise price	$4.04
Year Granted 2009 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	89,251
Exercise price range minimum	$2.01
Exercise price range maximum	$5.60
Weighted average exercise price (CDN$)	$4.49
Number of options exercisable	89,251
Weighted average exercise price	$4.49
Year Granted 2010 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	210,435
Exercise price range minimum	$5.52
Exercise price range maximum	$6.45
Weighted average exercise price (CDN$)	$5.97
Number of options exercisable	210,435
Weighted average exercise price	$5.97
Year Granted 2011 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	371,085
Exercise price range minimum	$2.73
Exercise price range maximum	$7.65
Weighted average exercise price (CDN$)	$4.08
Number of options exercisable	293,561
Weighted average exercise price	$4.29
Year Granted 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	1,146,610
Exercise price range minimum	$2.73
Exercise price range maximum	$7.18
Weighted average exercise price (CDN$)	$4.21
Number of options exercisable	728,613
Weighted average exercise price	$4.34
Year Granted 2013 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	1,622,528
Exercise price range minimum	$1.27
Exercise price range maximum	$3.33
Weighted average exercise price (CDN$)	$2.58
Number of options exercisable	579,151
Weighted average exercise price	$2.75
Year Granted 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	338,288
Exercise price range minimum	$0.47
Exercise price range maximum	$1.94
Weighted average exercise price (CDN$)	$1.53
Number of options exercisable	0
Weighted average exercise price	$0

STOCK_BASED_COMPENSATION_Detai2

STOCK BASED COMPENSATION (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted during the year	349,015	2,148,146	1,390,225
Weighted average grant date fair value of stock options granted during the year (CDN$)	$0.82	$1.21	$1.92
Risk-free interest rate	1.59%	1.45%	1.35%
Dividend yield	0.00%	0.00%	0.00%
Expected life of the options	4 years 10 months 24 days	4 years 3 months	4 years 3 months
Expected volatility of the underlying stock	62.13%	58.81%	68.29%

STOCK_BASED_COMPENSATION_Detai3

STOCK BASED COMPENSATION (Details 3) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation	$1,524	$1,885	$1,559
Administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation	723	939	693
Selling and Marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation	387	499	449
Customer Support and Operations
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation	231	223	152
Research and Development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation	$183	$224	$265

STOCK_BASED_COMPENSATION_Detai4

STOCK BASED COMPENSATION (Details 4) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options, Balance at begining of period	3,158,353	2,314,466	1,603,300
Number of options, Granted during the year	349,015	2,148,146	1,390,225
Number of options, Vested during the year	-1,128,345	-845,438	-583,388
Number of options, Forfeited during the year	-501,837	-458,821	-95,671
Number of options, Balance at end of period	1,877,186	3,158,353	2,314,466
Weighted average grant date fair value, Balance at begining of the period	$1.53	$2.17	$2.59
Weighted average grant date fair value, Granted during the year	$0.82	$1.21	$1.92
Weighted average grant date fair value, Vested during the year	$1.76	$2.26	$2.76
Weighted average grant date fair value, Forfeited during the year	$1.20	$1.89	$1.98
Weighted average grant date fair value, Balance at end of the period	$1.35	$1.53	$2.17

STOCK_BASED_COMPENSATION_Detai5

STOCK BASED COMPENSATION (Details Textual) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Common Stock Shares Outstanding Percentage	15.00%
Common Stock Shares Percentage	25.00%
Increase Common Stock Shares Percentage	6.25%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	90 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	$0	$133	$707
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	1,651
Share Based Compensation Arrangement By Share Based Payment Weighted Average Vesting Term	2 years 1 month 6 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$1,786	$1,841	$1,614

DEFINED_CONTRIBUTION_EMPLOYEE_1

DEFINED CONTRIBUTION EMPLOYEE PENSION PLAN (Details Textual) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Defined Contribution Plan, Employer Matching Contribution, Percent	50.00%
Defined Contribution Plan, Cost Recognized	$328	$294	$271
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	3.00%

INCOME_TAX_EXPENSE_Details

INCOME TAX EXPENSE (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Summary of Loss From Operations Before Income Taxes By Taxing Jurisdiction [Line Items]
Net loss before taxes	($30,145)	($41,856)	($27,670)
Canada [Member]
Summary of Loss From Operations Before Income Taxes By Taxing Jurisdiction [Line Items]
Net loss before taxes	-17,998	-40,970	-28,501
United States [Member]
Summary of Loss From Operations Before Income Taxes By Taxing Jurisdiction [Line Items]
Net loss before taxes	-12,994	-1,092	361
Other [Member]
Summary of Loss From Operations Before Income Taxes By Taxing Jurisdiction [Line Items]
Net loss before taxes	$847	$206	$470

INCOME_TAX_EXPENSE_Details_1

INCOME TAX EXPENSE (Details 1) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Statutory federal and provincial tax rate									27.00%	27.00%	27.00%
Expected tax recovery at statutory rate									($8,140)	($11,301)	($7,490)
Foreign income taxed at higher rates									-892	-68	25
Permanent differences and other									529	339	243
Uncertain tax position									33	0	0
Research and development tax credits									2,419	-1,569	0
Deferred Revenue									1,825	0	0
Deferred True-up									4,225	0	0
Gain on Sale of Assets									2,703	0	0
Valuation allowances									-2,460	12,743	7,308
Income tax expense	$374	($11)	($138)	$17	$112	$6	$10	$16	$242	$144	$86

INCOME_TAX_EXPENSE_Details_2

INCOME TAX EXPENSE (Details 2) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Non-capital losses carried forward	$29,668	$25,550
Capital assets	2,012	653
Intangible assets	-3,719	-2,271
Research and development expenditures	9,293	12,807
Research and development tax credits	13,947	16,623
Stock based compensation	750	506
Reserves not taken for tax purposes	1,050	1,593
Total deferred tax assets	53,001	55,461
Valuation allowance	-53,001	-55,461
Net deferred tax asset	$0	$0

INCOME_TAX_EXPENSE_Details_3

INCOME TAX EXPENSE (Details 3) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Balance at December 31, 2013	$0
Additions for tax positions of prior years	33
Balance at December 31, 2014	$33

INCOME_TAX_EXPENSE_Details_Tex

INCOME TAX EXPENSE (Details Textual) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Tax Credit Carryforward [Line Items]
Deferred Tax Asset Deductible Research and Development Expenditure	$34,419
Operating Loss Carryforwards, Expiration Date	2027
Unrecognized Tax Benefits, Income Tax Penalties Accrued	6	0
Canada [Member]
Tax Credit Carryforward [Line Items]
Non Capital Losses	87,969
U.S. federal [Member]
Tax Credit Carryforward [Line Items]
Tax Credit Carryforward, Amount	9,096
Non Capital Losses	16,493
Provincial [Member]
Tax Credit Carryforward [Line Items]
Tax Credit Carryforward, Amount	7,306
U.S. state [Member]
Tax Credit Carryforward [Line Items]
Non Capital Losses	$6,951

FINANCIAL_VALUE_MEASUREMENTS_D

FINANCIAL VALUE MEASUREMENTS (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted cash	$371	$7,500
Cash And Cash Equivalents At Carrying Value	5,002	6,382	19,060	40,425
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash	5,002	6,382
Restricted cash	371	7,500
Cash And Cash Equivalents At Carrying Value	5,373	13,822
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash	0	0
Restricted cash	0	0
Cash And Cash Equivalents At Carrying Value	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash	0	0
Restricted cash	0	0
Cash And Cash Equivalents At Carrying Value	$0	$0

COLLABORATIVE_ARRANGEMENTS_Det

COLLABORATIVE ARRANGEMENTS (Details Textual) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues									$28,891	$46,042	$52,392
Research and Development Expense	1,869	1,532	1,761	1,602	11,211	2,339	1,534	2,739	6,764	17,823	14,556
Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues									0	72	2,092
Cost of Revenue, Total									0	91	2,092
MRgRT platform [Member] | Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenues										834	3,001
Research and Development Expense										8,294
Cost of Revenue, Total										958	1,582
Research and Development
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and Development Expense									313	157	0
Research and Development | Validation Projects [Member] | Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Allocation Of Advance Payments Received									$230	$230	$230

RESTRUCTURING_COSTS_Details

RESTRUCTURING COSTS (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
One-time employee termination benefits
Restructuring Cost and Reserve [Line Items]
Balance at beginning of the year	$157	$1,341	$0
Incurred	0	0	1,383
Paid	-157	-879	-42
Adjustments	0	-305	0
Balance at the end of the year	0	157	1,341
Contract termination costs
Restructuring Cost and Reserve [Line Items]
Balance at beginning of the year	2,125	0	0
Incurred	0	2,125	0
Paid	-635	0	0
Adjustments	-51	0	0
Balance at the end of the year	1,439	2,125	0
Other associated costs
Restructuring Cost and Reserve [Line Items]
Balance at beginning of the year	630	72	0
Incurred	123	3,619	72
Paid	-579	-2,800	0
Adjustments	-128	-261	0
Balance at the end of the year	$46	$630	$72

RESTRUCTURING_COSTS_Details_1

RESTRUCTURING COSTS (Details 1) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
One-time employee termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring costs	($305)	$1,383
One-time employee termination benefits | Administrative
Restructuring Cost and Reserve [Line Items]
Restructuring costs	-66	279
One-time employee termination benefits | Sales and marketing
Restructuring Cost and Reserve [Line Items]
Restructuring costs	0	41
One-time employee termination benefits | Customer Support and Operations
Restructuring Cost and Reserve [Line Items]
Restructuring costs	-69	643
One-time employee termination benefits | Research and Development
Restructuring Cost and Reserve [Line Items]
Restructuring costs	-170	420
Contract termination costs
Restructuring Cost and Reserve [Line Items]
Restructuring costs	2,125	0
Contract termination costs | Administrative
Restructuring Cost and Reserve [Line Items]
Restructuring costs	2,125	0
Contract termination costs | Sales and marketing
Restructuring Cost and Reserve [Line Items]
Restructuring costs	0	0
Contract termination costs | Customer Support and Operations
Restructuring Cost and Reserve [Line Items]
Restructuring costs	0	0
Contract termination costs | Research and Development
Restructuring Cost and Reserve [Line Items]
Restructuring costs	0	0
Other associated costs
Restructuring Cost and Reserve [Line Items]
Restructuring costs	3,358	72
Other associated costs | Administrative
Restructuring Cost and Reserve [Line Items]
Restructuring costs	1,112	21
Other associated costs | Sales and marketing
Restructuring Cost and Reserve [Line Items]
Restructuring costs	18	0
Other associated costs | Customer Support and Operations
Restructuring Cost and Reserve [Line Items]
Restructuring costs	715	22
Other associated costs | Research and Development
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$1,513	$29

RESTRUCTURING_COSTS_Details_Te

RESTRUCTURING COSTS (Details Textual) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	$6.80
One-time employee termination benefits
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Incurred Cost	1.1
Restructuring and Related Cost, Expected Cost	1.1
Contract termination costs
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Incurred Cost	2.1
Restructuring and Related Cost, Expected Cost	2.1
Other associated costs
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Incurred Cost	3.4
Restructuring and Related Cost, Expected Cost	$3.60

LONG_TERM_DEBT_NET_OF_DISCOUNT2

LONG TERM DEBT, NET OF DISCOUNT (Details) (USD $)	12 Months Ended			1 Months Ended		0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 24, 2014	Sep. 23, 2014	Sep. 16, 2013
Debt Instrument [Line Items]
Grant date fair value of warrants granted during the year	$0.82	$1.21	$1.92
Warrant [Member]
Debt Instrument [Line Items]
Grant date fair value of warrants granted during the year				$0.09	$0.30	$0.86
Risk-free interest rate				1.27%	1.27%	2.36%
Dividend yield				0.00%	0.00%	0.00%
Expected life of the warrants	4 years 3 months			2 years 11 months 23 days	3 years 2 months 23 days	4 years 3 months
Expected volatility of the underlying stock				60.93%	60.93%	59.96%

LONG_TERM_DEBT_NET_OF_DISCOUNT3

LONG TERM DEBT, NET OF DISCOUNT (Details 1) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Long-term Purchase Commitment [Line Items]
2015	$5,401
2016	10,554
2017	9,801
2018	9,040
2019	$14

LONG_TERM_DEBT_NET_OF_DISCOUNT4

LONG TERM DEBT, NET OF DISCOUNT (Details Textual) (USD $)	1 Months Ended	0 Months Ended	12 Months Ended			1 Months Ended
	Sep. 23, 2014	Sep. 16, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Feb. 28, 2014	Dec. 24, 2014
Debt Instrument, Face Amount		$25,000,000
Percentage Of Prepayment Fee		4.00%
Percentage Of Repayment Amount On Principal Amount		104.00%
Minimum Amount Maintain Cash And Cash Equivalents Including Restricted Cash		7,500,000	7,500,000
Debt Instrument, Interest Rate, Stated Percentage		9.00%
Debt Instrument Facility Fee		500,000
Debt Instrument Facility Fee To Other Professionals		1,400,000
Debt Instrument Facility Fee Amortized Term		5 years	3 years 9 months
Note Discount		4,800,000	4,500,000	4,500,000
Interest Expense, Debt			2,423,000	665,000	0
Debt discount amortization			494,000	340,000	0
Debt issuance cost amortization			1,387,000	133,000	0
Long Term Debt Effective Interest Rate			9.44%
Paid-in-Kind Interest			1,791,000	665,000	0
Class of Warrant or Right, Exercise Price of Warrants or Rights	$0.70	$1.94					$0.35
Increase (Decrease) in Other Noncurrent Liabilities	1,100,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		6,100,000
Long-term Debt, Fair Value			26,600,000
Adjustments To Additional Paid In Capital Other			3,000,000	18,237,000	-989,000
City of Minnetonka [Member]
Debt Instrument, Interest Rate, Stated Percentage						0.00%
Long-term Debt, Gross						500,000
Debt Instrument, Term						5 years
Debt Instrument, Frequency of Periodic Payment						the City will forgive up to $350 of the loan, with equal monthly payments of the remaining principal balance due beginning January 2016 through January 2019.
Long-term Debt [Member]
Paid-in-Kind Interest			2,456,000	665,000
Adjustments To Additional Paid In Capital Other			$281,000

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
2015	$1,763
2016	1,493
2017	1,236
2018	1,209
2019	1,202
Thereafter	$4,007

COMMITMENTS_AND_CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Textual) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Operating Leases, Rent Expense	$1,852	$1,681	$770

SHARE_CAPITAL_AND_BASIC_AND_DI1

SHARE CAPITAL AND BASIC AND DILUTED LOSS PER SHARE (Details Textual) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 24, 2014	Sep. 23, 2014	Sep. 16, 2013	Jun. 24, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common Stock Authorized Shares	unlimited
Preferred Stock Authorized Shares	unlimited
Issuance of stock on exercise of employee stock options (in shares)	0	219,755	1,086,102
Proceeds From Issuance Of Common Stock	$3,000	$18,931	$2,420
Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right Description	Each unit consisted of one common share and one and a quarter common share purchase warrants.
Class of Warrant or Right, Exercise Price of Warrants or Rights				$0.35	$0.70	$1.94
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	4,528,172	463,915	452,344
Public Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, New Issues		5,750,000
Proceeds From Issuance Of Common Stock		20,100
Stock Units Issued During Period Shares And Warrants New Issues	10,563,380
Shares Issued, Price Per Share	$0.28	$3.50
Proceeds From Issuance Of Stock Units	3,000
Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right Description	Each unit consists of one common share of the Company and one and a quarter common share purchase warrants. Each warrant is exercisable into one Common Share
Public Offering [Member] | Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights							$0.37
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of stock on exercise of employee stock options (in shares)		219,755	1,086,102
Stock Issued During Period, Value, Issued for Cash		484	2,420
Additional Paid-In Capital [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Value, Issued for Cash		$209	$989

SEGMENTED_INFORMATION_Details

SEGMENTED INFORMATION (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]
Sales	$28,891	$46,042	$52,392
Canada [Member]
Segment Reporting Information [Line Items]
Sales	1,895	3,934	3,803
United States [Member]
Segment Reporting Information [Line Items]
Sales	23,803	24,782	32,569
Europe and Middle East [Member]
Segment Reporting Information [Line Items]
Sales	702	10,603	2,085
Asia Pacific
Segment Reporting Information [Line Items]
Sales	$2,491	$6,723	$13,935

SEGMENTED_INFORMATION_Details_

SEGMENTED INFORMATION (Details Textual) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Net	$17,591	$36,459	$47,285
Four Customers [Member]
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Net			23,054
Concentration Risk, Percentage			44.00%
Customers Each Individually [Member]
Segment Reporting Information [Line Items]
Concentration Risk, Percentage	10.00%	10.00%	10.00%
Three Customers [Member]
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Net		20,453
Concentration Risk, Percentage		44.00%
Two Customers [Member]
Segment Reporting Information [Line Items]
Sales Revenue, Goods, Net	$11,743
Concentration Risk, Percentage	41.00%

RELATED_PARTY_TRANSACTIONS_Det

RELATED PARTY TRANSACTIONS (Details Textual) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 24, 2014	Sep. 23, 2014	Sep. 16, 2013	Jun. 24, 2020
Related Party Transaction [Line Items]
Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party		$25	$396
Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right Description	Each unit consisted of one common share and one and a quarter common share purchase warrants.
Class of Warrant or Right, Exercise Price of Warrants or Rights				$0.35	$0.70	$1.94
Public Offering [Member]
Related Party Transaction [Line Items]
Stock Units Issued During Period Shares And Warrants New Issues	10,563,380
Shares Issued, Price Per Share	0.284	$3.50
Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right Description	Each unit consists of one common share of the Company and one and a quarter common share purchase warrants. Each warrant is exercisable into one Common Share
Subsequent Event [Member] | Public Offering [Member]
Related Party Transaction [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights							$0.37

QUARTERLY_DATA_UNAUDITED_Detai

QUARTERLY DATA (UNAUDITED) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenue	$9,558	$6,924	$4,258	$8,151	$9,985	$17,765	$10,226	$8,066
Cost of sales and services	5,854	4,537	2,342	6,226	7,222	10,984	7,117	5,046	18,959	30,369	34,594
Gross profit (exclusive of depreciation and amortization shown below)	3,704	2,387	1,916	1,925	2,763	6,781	3,109	3,020	9,932	15,673	17,798
As a percentage of sales	38.80%	34.50%	45.00%	23.60%	27.70%	38.20%	30.40%	37.40%
Operating expenses
Administration	1,841	1,710	1,839	1,740	4,803	2,280	2,833	2,410	7,130	12,326	8,224
Sales and marketing	1,623	1,791	2,008	1,707	2,905	2,300	2,522	2,259	7,129	9,986	9,833
Customer support and operations	2,197	2,400	2,388	2,228	3,048	2,889	2,984	2,436	9,213	11,357	8,612
Research and development	1,869	1,532	1,761	1,602	11,211	2,339	1,534	2,739	6,764	17,823	14,556
Depreciation and amortization	665	702	702	767	630	963	943	950	2,836	3,486	4,097
Total operating expenses	8,195	8,135	8,698	8,044	22,597	10,771	10,816	10,794	33,072	54,978	45,322
Operating loss before the following:	-4,491	-5,748	-6,782	-6,119	-19,834	-3,990	-7,707	-7,774	-23,140	-39,305	-27,524
Gain (loss) on asset disposals	-2	-206	12	0	-120	0	0	0	-196	-120	19
Foreign exchange gain (loss)	-842	-1,357	677	-710	-557	387	-483	-555	-2,232	-1,208	-125
Interest and other expense	-1,358	-1,092	-1,072	-1,055	-992	-195	-3	-33	-4,577	-1,223	-40
Net loss before taxes	-6,693	-8,403	-7,165	-7,884	-21,503	-3,798	-8,193	-8,362	-30,145	-41,856	-27,670
Income tax expense (benefit)	374	-11	-138	17	112	6	10	16	242	144	86
Net loss	($7,067)	($8,392)	($7,027)	($7,901)	($21,615)	($3,804)	($8,203)	($8,378)	($30,387)	($42,000)	($27,756)
Loss per share
Basic	($0.13)	($0.16)	($0.14)	($0.15)	($0.42)	($0.07)	($0.16)	($0.18)
Diluted	($0.13)	($0.16)	($0.14)	($0.15)	($0.42)	($0.07)	($0.16)	($0.18)

COMPARATIVE_FIGURES_Details_Te

COMPARATIVE FIGURES (Details Textual) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Deferred Revenue Arrangement [Line Items]
Systems revenue	$17,591	$36,459	$47,285
Services revenue	$11,300	$9,583	$5,107